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BUTYROPHENONES IN NARCOTIC WITHDRAWAL

ABSTRACT
Narcotic dependence was established by continuous intravenous infusion of gradually increasing doses of morphine.
Several days at the terminal concentration of morphine (100
mg/kg/day) was allowed prior to withdrawal.

Morphine with-

drawal body shakes were reliably observed upon the termination of continuous morphine infusion.

The administration of

morphine, methadone or _fentanyl, potent narcotic drugs, reliably abolished the occurrence of withdrawal body shakes 8
hours after the terf!lination of morphine infusion.
cotic antagonist naloxone or pentazocine

~ad

The nar-

no significant

effect on the rate of occurrence of withdrawal body shakes;
however, there was a slight trend towards an increase in the
frequency of this withdrawal index.

A wide variety of neuro-

leptics were investigated for their ability to reduce withdrawal.

The order of potency for reduction of withdrawal

body shakes on a mg/kg basis for those neuroleptics tested
was spiperone, benperidol, +butaclarriol, loxapine, oxiperomide,
haloperidol, spiramide, chlorpromazine, trifluoperazine,
pimozide and pipamperone.

The dopaminergic agonists amphet-

amine, apomorphine and L-IX>PA were also found to dose dependently reduce withdrawal · body shakes.

Azaperone, a

butyrophenone possessing high alpha noradrenergic blocking
potency, reduces withdrawal body shakes in a dose related
manner, while the alpha adrenergic blocker phenoxybenzamine
ii

and the beta adrenergic blocker propronalol failed to reduce
withdrawal shakes to any significant extent.

Dose dependent

decreases in morphine withdrawal body shakes were produced
by clonidine and desmethylimipramine, adrenergic agonists.
Reserpine and alpha-methyl-p-tyrosine also reduced withdrawal
shakes, but the effect was dose dependent for only reserpine.
The serotoninergic agents fluoxetine, 5-HTP and methysergide
were without effect on the occurrence of withdrawal body
shakes at the doses tested.

A slight but non-significant in-

crease in the rate of withdrawal shakes was observed after
the administration of the anticholinergic drugs atropine,
benztropine, dexetimide and scopolamine. Conversely, the
cholinergic agonists physostigmine and pilocarpine, reduced
withdrawal body shakes in a dose related fashion.

Modifica-

tion of gabaminergic system by the administration of bicuculline, depakene and picrotoxin had no significant effect.
Chlordiazepoxide, flurazepam and pentobarbital, sedativehypnotic agents, did not produce dose dependent effects on
the occurrence of withdrawal shakes.

However, the highest

dose of each sedative hypnotic employed did reduce withdrawal
body shakes.

The exact mechanism by which neuroleptics re-

duce withdrawal is not known.

Manipulation of each of the

transmitters effect by neuroleptics indicates that dopamine
and acetylcholine are involved in mediating the reduction in
withdrawal body shakes.

The fact that the antiwithdrawal

activity of certain neuroleptics is reversed by the narcotic
antagonist naloxone _implicates opiate receptor mechanisms.
iii

However, not all neuroleptics were antagonized by naloxone,
suggesting that neuroleptics may be wo rking at more than one
site to reduce withdrawal. Thus neuroleptics may be reducing withdrawal body shakes by several different mechanisms.
The data gathered from these studies suggest a role for cholinergic, dopaminergic and narcotic mechanisms in the antiwi thdrawal activity of neuroleptic drugs .
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INTRODUCTION

Treatment of narcotic dependence invariably requires
the discontinuation of the abused narcotic . Discontinuation
of narcotic drugs results in an abstinence syndrome which
is so aversive that patients hesitate undergoing treatment
and continue using illicit narcotics.

Presently, methadone

is employed to prevent the narcotic abstinence syndrome. Although methadone is an effective agent in blocking withdrawal, it is a narcotic drug (Jaffe and Martin, 1975) and
is therefore likely to perpetuate the underlying cause of
narcotic dependence.

Thus chemotherapeutic approaches to

the treatment of narcotic addiction require the development
of non-addicting drugs which are able to successfully relieve the withdrawal syndrome.

This research was undertaken

to investigate the effectiveness of butyrophenone neuroleptics and related compounds in relieving norphine withdrawal
body shakes in the rat.

The mechanism by which these drugs

inhibit the narcotic withdrawal syndrome was also explored.
Interest in the use of butyrophenones in narcotic
withdrawal was stimulated by their known effectiveness in
blocking brain dopamine receptors.

Several lines of evi-

dence have suggested that supersensitivity of dopamine receptors is int imately involved in the development of
1
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narcotic dependence.

This evidence has been in part gener-

ated by studies of morphine withdrawal aggression.

Withdrawal

from morphine elicits intense aggression upon grouping of dependent rats.

Pretreatment with L-dihydroxyphenylalanine

(L-DOPA), amphetamine or apomorphine enhanced that aggression
severalfold.

These agents are known to stimulate brain dop-

amine receptors.

Haloperidol, a potent dopaminergic blocking

agent, inhibits this aggression (Puri and Lal, 1973).

Sever-

al other studies have suggested a role for brain dopamine in
narcotic dependence.

Lesions placed stereotaxically in mon-

keys at the origin of the nigrostriatal system and the
tegmenti ventralus, known to be mainly dopaminergic pathways
(Anden et al., 1964) abolish craving for morphine and the
signs of withdrawal (Pozuelo and Kerr, 1972).

Spontaneous

aggression is reliably seen when morphine dependent rats are
grouped after 30 days of abstinence. Electrolytic lesions of
the nigrostriatal nerve tract abolished this morphine withdrawal aggression.

A low dose of the dopaminergic stimulant

apomorphine was effective in reinstating the withdrawal aggression in these lesioned animals (Gianutsos et al., 1973;
1974). For a detailed review of narcotic dependence and
brain dopamine see Lal (1975).
More recently, another line of evidence became available to suggest that butyrophenones may serve as nonaddicting
substitutes for narcotic drugs in the treatment of withdrawal.
Clay and Brougham (1975) reported a competition for binding
at selective brain sites between the butyrophenone, haloperidol

3

and the narcotic antagonist, naloxone, suggesting that haloperidol binds with narcotic-specific receptors.
al.

(1976) and Leysen et al.

Creese et

(1976) have shown marked affin-

ity between several neuroleptics and opiate binding sites to
suggest that the binding was due to a structural feature
common to both narcotics and butyrophenone type neuroleptics.
Their conclusions are supported by a number of pharmacological
similarities between neuroleptics and narcotics (Lal et al.,
1975; Lal et al., 1976).

It therefore became apparent that

butyrophenones and related drugs are likely to block withdrawal signs.

Results from preliminary experiments with

haloperidol in laboratory animals (Lal et al., 1971; Lal and
Numan, 1976; Martin et al., 1974) and human patients (Karkalas
and Lal, 1973) were encouraging.
The present study was undertaken to investigate butyrophenones and related drugs in reducing morphine withdrawal
body shakes, an important sign of narcotic withdrawal in rats.
Morphine withdrawal body shakes are employed as an index of
withdrawal since they are a consistent and objective sign of
narcotic withdrawal (Gianutsos et al., 1975, Martin et al.,
1963).

The anti-withdrawal mechanism of butyrophenones were

explored in detail.

The specific hypothesis to be tested

with respect to the anti-withdrawal mechanisms of neuroleptic drugs are that these drugs interfere with transmitter
substances in the brain thereby reducing withdrawal intensity
or alternatively these drugs bind to narcotic receptors to
suppress withdrawal.

4

Neuroleptics have many important and well deroonstrated
effects on neurotransmitters such as dopamine, norepinephrine,
serotonin,r-aminobutyric acid, and acetylcholine.

It is

conceivable that the anti-withdrawal actions of neuroleptic
agents are mediated by their effects on the aforementioned
neurotransmitters.

Alternatively, in view of the fact that

neuroleptic drugs have been shown to bind to opiate receptor
sites within the central nervous system it is possible that
this binding is responsible for the anti-withdrawal activity
of neuroleptics.
In order to test the hypothesis that the anti-withdrawal mechanism of neuroleptics are related to effects on
neurotransmitters it was necessary to roodify the activity of
each transmitter individually.

This was accomplished by

studying the effects of specific neurotransmitter agonist and
antagonist on morphine withdrawal body shakes.

To determine

if anti-withdrawal activity is due to antagonism of dopamine
receptor, a number of anti-dopamine drugs were adrninstered.
The dopaminergic antagonists employed were haloperidol, benperidol, spiroimide, oxiperimide, spiperone, loxapine, chlo r promazine, trifluoperazine, pimozide, butaclamol and pipamperone. Stimulation of dopamine receptors was accomplished
by the administration of apomorphine, L-DOPA and amphetamine.
Norepinephrine receptors were antagonized by the use of
propranolol, phenoxybenzarnine and azaperone. Clonidine, imipramine, tranylcypromine and amitripty line were the noradrenergic agaonists employed.

Synthesis and storage of the

5

catecholamines was inhibited by the administration of alphamethy-p-tyrosine and reserpine, respectively.

Serotonin

activity was mimicked by 5-hydroxytryptophan (5-HTP) and
fluoxetine. Antagonism of serotonergic receptors was achieved
by administration of methysergide. Acetylcholine was also
systematically explored.

The following anticholinergic drugs

were investigated - scopolamine, atropine, benztropine and
dexetimide while the cholinomimetics employed were pilocarpine, deanol, choline chloride, oxotremorine and physostigmine. Additionally, the effect of the gabaminergic agents
bicuculline, depakene and picrotoxin were investigated for
their effects on morphine withdrawal body shakes.

Chlordi-

azepoxide, flurazepam and pentobarbital, sedative-hypnotic
agents, were administered to investigate the possibility
that neuroleptics induce these anti-withdrawal effects by
their ability to produce sedation.

A dose response curve

was established for all drugs employed in 100difying neurotransmitter activity.

These experiments will determine if

reduction of withdrawal intensity is due to modification of
dopamine, norepinephrine, serotonin, acetylcholine, or
-aminobutyric acid activity.

K'

A series of saline injections

were interspersed with drug trials to control for a spontaneous decrease in withdrawal intensity, the effect of handling and the injection procedure.
The hypothesis that the anti-withdrawal activity of
neuroleptics is mediated by an interaction with narcotic
binding sites or release of endorphins was tested with the

6

aid of naloxone

a specific narcotic antagonist.

Neuroleptics

which were found t o reduce morphine withdrawal body shakes were
interacted with naloxone.

Theoretically, if neuroleptic bind-

ing to opiate receptors mediates the anti-withdrawal activity
then this effect should be reversed by the narcotic antagonist, naloxone.

The maximum effective dose of each neurolep-

tic was administered in conjunction with naloxone to determine
if the effect was reversible by this narcotic antagonist.
This research has significance in that evidence for
the role of various neurotransmitters in the expression of
morphine withdrawal body shakes will be gathered.

It will

give expanded insight into the role of dopamine systems in
narcotic dependence and withdrawal.

Drugs which have poten-

tial for use in reducing the narcotic withdrawal syndrome in
humans will hopefully be found.

Additionally, further in-

formation on the pharmacological mode of action of narcotics
and neuroleptics will be achieved.

II
LITERATURE SURVEY
A.

The Narcotic Withdrawal Syndrome in the Rat
The study of the pathophysiology of narcotic depend-

ence requires an appropriate animal model • The rat has proven
to be a useful subject for the study of the mechanism of narcotic addiction since it is easily made dependent on narcotics.
Dependence in the rat has been produced by chronic intraperitoneal injections of morphine sulfate (Martin et al., 1963),
intravenous injections (Numan et al., 1975), subcutaneous implantation of morphine alkaloid pellets (Collier et al., 1972;
Wei and Way, 1975), administration of narcotics in the drinking water (Gianutsos et al., 1975a) or continuous intraperitoneal infusion (Teiger, 1974; Harris, 1976).
The withdrawal syndrome exhibited by the rat is consistent, reliable and can be objectively measured (for review
see Gianutsos et al., 1975a).

This syndrome may be brought

about either by administration of a narcotic antagonist or
by the abrupt termination of chronic morphine administration.
The withdrawal precipitated by an antagonist is immediate,
shortlived and quantifiable.

However, except for special

circumstances, i t is never clinically encountered in man. In
contrast, the spontaneous withdrawal caused by cessation of
narcotic drug administration has wider application to research and the screening of antiabstinence drugs
et al., 1975a).

7

(Gianutsos
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1.

Withdrawal Signs, Acute and Protracted
The withdrawal syndrome can be divided into two phases,

primary abstinence and protracted abstinence (Martin and
Sloan, 1971; Martin, 1972).

The primary abstinence syndrome

begins to appear 12-24 hours after discontinuing chronic morphine.

It consists of the following symptoms:

"wet shakes,"

loss of body weight, decreased metabolic rate, increased urination and defecation, decreased fluid consumption, hypothermia, sleeplessness, irritability on handling, enhanced
excretion of norepinephrine and epinephrine.

In addition,

there is a decline in the voltage output of the EEG (Khazan
et al., 1967), writhing (Buckett, 1964), social aggression
(Lal et al., 197la), ptosis and piloerection (Wikler et al.,
1960). This syndrome lasts for approximately 72 hours after
which the syndrome begins to change (Gianutsos et al., 1975a).
During the protracted phase, food and water intake, body
weight, temperature and locomotor activity increase above
normal levels and may persist for several months

(Martin et

al., 1963). Additionally, there is a continuation of wet
shakes (Martin et al., 1974) and EEG abnormalities (Khazan
and Colasanti, 1971) during the protracted phase.

Many of

the other symptoms . begin to return to normal levels during
this time (Gianutsos et al., 1975a).
2.

Morphine Withdrawal Body Shakes
Body shakes constitute a widely used and reliable

criterion of narcotic withdrawal (Martin et al., 1963;
Gianutsos et al., 1975a). They are defined as violent shaking

9

movements of the head and/or body of the rat which resemble
the action of an animal that has been drenched with water and
are readily distinguishable from tremors or jerky movements
(Gianutsos et al., 1975a).

The frequency at which wet shakes

occur is greatest shortly after handling the rat or after
changing its place of residence and decreases with time
(Gianutsos et al., 1975a).

Withdrawal body shakes are most

intense 24 hours after the last morphine injection and begin
to decrease by 72 hours of withdrawal

(Gianutsos et al.,

1975a).
Withdrawal body shakes have been shown to occur upon
abrupt termination of morphine treatment (Martin et al., 1963;
Gianutsos et al., 1975a), the administration of narcotic antagonist (Wei et al., 1973c) and to a lesser extent in drug
naive rats

(Martin et al., 1963; Gianutsos et al., 1975a).

Rats rendered chronically epileptic by the implantation o f
cobalt in the right parietal cortex exhibited a significant
number of wet dog shakes (Colasanti et al., 1975). Wet dog
shakes have also been elicited in non-addicted rats without
concomitant symptoms by the administration of [(4-chlorobenzylidene-amino)-oxy)] isobutyric acid (Jahn and Mixich,
1976).

Additionally, repetitive shaking movements can be

elicited in pentobarbital anesthetized rats after immersion
in water.

The frequency of shakes is inversely related to

the temperature of the water and is a function of the drop
in body temperature (Wei et al., 1973b).

However, hypo-

thermia per se was not found to be a necessary condition for

10

eliciting shaking behavior (Wei et al., 1973b). This wet shake
response was facilitated by stimuli to the ear (Wei et al.,
1973b).

The endogenous morphinomemetic brain peptides meten-

kephalin and~, B and
acute episodes

/j' endorphins

have been found to produce

of wet-dog-like shaking behavior in animals

not previously treated with drugs.

This response began with-

in 90 seconds after lateral ventricular injection (Bloom et
al., 1976). These shaking episodes were found to be more intense and prolonged with

the~

and d' -endorphins.

The ad-

ministration of naloxone completely abolished these wet-dogshaking episodes from lateral ventricular peptide injections
(Bloom et al., 1976).

Intraperitoneal administration of

n-dipropylacetate (DPA) to naive rats produced abstinence
behavior which included shaking (de Boer et al., 1977).

This

behavioral effect of DPA, which increases GABA concentrations
in the brain, is suppressed by bicuculline and morphine
(de Boer et al., 1977).
Several investigations have been undertaken to study
the neuroanatomical pathways related to morphine abstinence,
in particular the effects of brain lesions on the wet shake
behavior of morphine abstinence.

Wei et al.

(1973a) have

explored the brains of morphine-dependent rats for areas
sensitive to naloxone-precipitated withdrawal. Wet shakes
were most frequently elicited after application of naloxone
to the medial thalamus and in medial areas of the diencephalic-mesencepholic junctures.

Neocortical, hippocampal,

hypothalamoic, tegmental, lateral thalamic and striatal
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areas of the brain were found less sensitive to naloxoneprecipitated withdrawal body shakes (Wei et al., 1972; 1973a).
Transverse brain lesions made at the mid-collicular level
completely inhibit the wet shake response to ice water in nontolerant rats, while lesions at the mid-thalamic level did
not significantly affect the wet shake response (Wei et al.,
1973a).

The areas in the rat brain where knife cuts alternate

the wet shake response to ice water and where naloxone precipitates the shaking behavior of the morphine abstinence
syndrome (Wei et al., 1973a) bears considerable resemblance
to the primary motor center for shivering in the cat and brain
areas thought to be intimately related to subcortical mechanism for arousal and emotional behavior (Wei et al., 1973a).
In addition to those studies employing lesions of
various brain regions to study the neuroanatomical pathways
related to morphine abstinence, there are studies which have
employed intraventricular injections of morphine antagonist
into dependent animals. Withdrawal signs have been precipitated by injection of morphine antagonist into the ventricular
system of dependent rats

(Watanabe, 1971), rabbits (Herz et

al., 1972) and monkeys (Eidelberg and Barstow, 1971).
withdrawal pattern precipitated

The

by intraventricular injection

generally resembles that observed after systemic administration
of morphine antagonist (Laschka et al., 1976a).

When antago-

nists were applied into restricted parts of the ventricular
system of rabbits, severe withdrawal signs were e l icited after
injection of antagonists into the 4th ventricle, whereas
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only weak signs were observed when antagonists were administered into restricted parts of the anterior ventricular system,
consisting of the lateral ventricles and third ventricle
(Herz et al., 1972).

Similar studies in the rat show a weak

withdrawal syndrome when the antagonists could spread only
within the lateral ventricles and the 3rd ventricle; however,
when antagonist administration was restricted to the 4th
ventricle, strong withdrawal signs were elicited by small
doses

(Laschka et al., 1976b). Following intraventricular

injection of antagonist wet dog shakes were readily obtained;
this was most clearly dem:>nstrated by the fact that SH 254,
a partial agonist, induces wet dog shakes at low doses following intraventricular administration but which after systemic
administration induces almost no wet dog shakes (Laschka
et al., 1976).

Similarly, naloxone which induced only a few

wet dog shakes in rats made dependent by pellet implantation

••
(Blasig
et al., 1976), elicits this symptom reliably after
intraventricular injection (Laschka et al., 1976a).

These

studies lead to the conclusion that brain structures located
in the anterior parts of the floor of the 4th ventricle and
caudal parts of the periaqueductal gray matter are important
sites in the development of morphine physical dependence.

B.

The Effect of Drugs on the Morphine Withdrawal Syndrome
1.

Narcotic Drugs
During abstinence from morphine, the rat exhibits a

large variety of measurable signs (Martin et al., 1963;
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Gianutsos et al., 1975a) which may be prevented by both morphine and methadone (Gianutsos et al., 1975a) .

Withdrawal

wet shakes, writhing, piloerection, ptosis and aggression are
blocked by the administration of morphine and methadone.
Weight loss during withdrawal is not immediately reversed by
narcotic administration; however, if morphine is continually
administered, the occurrence of weight loss is prevented.
Methadone initially prevents weight loss in morphine withdrawn rats, but a tolerance rapidly develops to this effect
(Gianutsos et al., 1975a).

Withdrawal hypothermia is re-

versed b y morphine administration; however, methadone is only
partially able to reverse this withdrawal sign (Gianutsos
et al., 1975a).

It should be noted that the effectiveness

of morphine and methadone is short-lived, lasting less than
24 hours, after which the syndrome again emerges.

The ef-

fectiveness of methadone on certain parameters, body weight
loss and wet shakes, disappears during repeated treatment,
indicating the rapid development of tolerance (Gianutsos
et al., 1975a).

In contrast to the spontaneous withdrawal

syndrome, the withdrawal precipitated by an antagonist is
very difficult, if not impossible, to suppress by drugs, including opiates (Gianutsos et al., 1975a).

Morphine has

been found to suppress the withdrawal abstinence syndrome in
the dog in a dose-related manner.

However, morphine was less

effective in suppressing abstinence in dogs with a high level
of dependence (Martin et al., 1974).

A wide variety of com-

pounds with diverse chemical structures which possess very
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potent morphine-like activity have been tested for their
ability to suppress abstinence in the morphine-dependent monkey.

Some of the chemical families test include the phenyl-

piperidines, benzimidazoles, benzomorphans, morphinans,
methadones and diazabicyclo-octanes.

These compounds have

been found to suppress abstinence in the morphine-dependent
monkey with varying degrees of potency (Villarreal, 1973).
Studies done at the Addiction Research Center at Lexington,
Kentucky also show these compounds to suppress morphine abstinence in man (Villarreal, 1973).
2.

Non-Narcotics Drugs
a.

Dopaminergic Agonist and Antagonist
Narcotic dependent rats undergoing withdrawal are

hyper-irritable and when placed together show vigorous fighting (Boshka et al., 1966; Lal, et al., 197la).

This aggres-

sion is blocked by continued treatment with morphine, but
emerges when drug administration is discontinued.

Aggression

in the rat consists of vocalizations, aggressive posture,
biting and other forms of attack which often leads to severe
injury or death (Lal, 1975a).

Haloperidol, a potent anti-

psychotic drug (Janssen, 1966), is very effective in blocking morphine withdrawal aggression (Puri et al., 1973; Lal,
1975b).

This aggression is also reduced by chlorpromazine,

a pentothiazine neuroleptic (Lal, 1975a}.
Wet-dog-like body shakes are a characteristic sign of
morphine withdrawal in rats

(Martin et al., 1963; Gianutsos

et al., 1975a}. Haloperidol has been found to produce a dose
dependent decrease in withdrawal shakes (Lal and Numan, 1976}.
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During morphine-withdrawal, animals learn to selfadminister narcotic drugs directly into the bloodstream at
high rates

(Weeks and Collins, 1968; Schuster, 1970; Numan

et al., 1975).

Intraperitoneal administration of haloperidol

given in small doses was shown to significantly decrease
morphine self-administration in addicted rats
and Hanson, 1972).

(Cimini-Venoma

This observation was later replicated in

the monkey by Pouzolo and Kerr (1972).

Spiramide, a buty-

rophenone neuroleptic, reduces the rate of self-administration of fentanyl, a potent narcotic (Lal and Hynes, 1977).
Haloperidol has also been found to decrease morphine reinforcement and inhibit relapse in post-addict rats

(Schwartz

and Marchok, 1974).
Haloperidol (Lal et al., 197lb) and pimozide (Cox et
al., 1975) prevent as well as reverse withdrawal hypothermia
in the morphine dependent rat.

Recently, Martin et al.

(1974) reported that haloperidol depressed certain aspects
of the morphine abstinence syndrome in the dog but not others.
Haloperidol proved to be more effective than morphine in
suppressing mydriasis and panting while it was relatively
less effective in reducing whining, gnawing and hindlimb
stepping movement (Martin et al., 1974).

Morphine withdrawal

jumping in the mouse is blocked by the administration of
haloperidol (Takemori et al., 1976).
Several years ago it was reported (Lal et al., 197lb)
that haloperidol reduced several withdrawal symptoms in
heroin addicts.

This initial study was replicated by Karkalas
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and Lal (1973) who compared haloperidol with methadone in 18
patients.

Haloperidol was found effective in completely block-

ing the withdrawal symptoms in half of the patients and compared well with methadone in this respect.

The failure of

several patients to respond to therapy was ascribed to the
use of too low a dose of haloperidol.

Those patients respond-

ing to haloperidol reported a reduction in their craving for
heroin (Karkalas and Lal, 1973).

These findings have been

replicated by a number of physicians (Lal and Hynes, 1977).
Haloperidol in conjunction with psychological and social
counseling, has been found useful in getting patients to give
up heroin for a six-month period or longer (Le Compte and
Friedman, 1974).
Chlorpromazine, a phenothiazine neuroleptic, has been
reported to reduce wet-dog shakes characteristic of precipitated withdrawal in the rat (Cicero et al., 1974).

Narcotic

withdrawal symptoms in newborn infants of drug dependent
mothers have been successfully controlled with chlorpromazine
(Glass, 1974; Kandall, 1976).

However, adult patients who

were being treated with both methadone and chlorpromazine requested the discontinuation of chlorpromazine because of adverse effects (Dufficy, 1973).
Morphine-withdrawal aggression is seen after the withdrawal of narcotic drugs

(Lal, 1975; Puri and Lal, 1973).

This aggression is enhanced by directly and indirectly acting
dopamine-receptor stimulants such as amphetamine, L-DOPA or
apomorphine (Puri and Lal, 1973).

DOPA has also been found
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to exacerbate withdrawal jumping, diarrhea, tremors, writhing and convulsions (Gunne, 1965).

Herz (1975) found L-DOPA

administered shortly before precipitating withdrawal induced
a dose-dependent increase in withdrawal jumping and a decrease
in wet-dog shakes.

Other signs such as diarrhea and ptosis

decreased, whereas rhinorrhea, lacrimation and salivation increased (Herz, 1975). Apomorphine, administered at doses
between 1 and 2.5 mg/kg, increased jumping, teeth chattering
and eye twitches but only the increase in jumping was statistically significant (Herz, 1975).

Ptosis and diarrhea were

both significantly decreased, with wet-dog shakes, writhing
and rhinorrhea yielding only equivocal results

(Herz, 1975).

Apomorphine has been found to reduce morphine withdrawal body
shakes in rats after the termination of morphine injections
(Hynes, 1975).
b.

Adrenergic Agonist and Antagonist
The alpha adrenergic stimulant clonidine has been

found effective in reducing body shakes, weight loss, ptosis,
urination, diarrhea, teeth chattering, salivation and ejaculation in dependent animals injected with naloxone (Meyer
and Sparber, 1976; Tseng et al., 1 9 75). Clonidine has been
found to potentiate escape attempts induced by naloxone in
dependent rats

(Tseng et al., 1975).

Inhibition of brain monoarnine oxidase by pargyline results in a potentiation of jumping behavior during naloxoneprecipitated withdrawal in mice (Iwamoto et al., 1971).

The

potentiation of jumping has been attributed to the elevation
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of biogenic amines in the central nervous system resulting
from monoamine oxidase inhibition.

Similarly, i t has been

reported that imipramine, a drug which inhibits the reuptake
of norepinephrine potentiates morphine withdrawal activity
in mice (Chiesa et al., 1968) and rats (Herz, 1975).

Low

doses of d - amphetamine and cocaine given shortly before precipitating withdrawal induced a dose-dependent increase in
jumping and a decrease in wet-dog shakes (Herz, 1975). Signs
such as diarrhea and ptosis decreased, whereas rhinorrhea,
lacrimation and salivation increased after amphetamine or
cocaine treatment (Herz, 1975).
Alpha adrenergic blockers such as phenoxybenzamine
have been found to produce a dose-related suppression of
diarrhea and wet-dog shakes in precipitated narcotic withdrawal

(Cicero et al., 1974).

Propranolol, the beta adrenergic

blocker, has been the subject of numerous and conflicting investigations.

Propranolol has been reported to prevent heroin

induced euphoria, cause the use of heroin to precipitate protracted withdrawal symptoms and reduce the craving for narcotics in ex-addicts (Grosz, 1972; Black and Grosz, 1974).
Other investigators have failed to find that propranolol
aggravated the opiate withdra wal syndrome and on the contrary
reported that i t provided some relief (Jacob et al., 1975).
Furthermore, no blockade by propranolol of the morphineinduced euphoria was found in man (Jacob et al., 1975).

Re-

sults obtained in the chronic spina l dog indicate that propranolol neither antagonized nor mimics the effects of morphine
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{Martin et al., 1974).

Similarly, the morphine Lo 50 in mice

is not altered by pretreatment with propranolol {Navarro et
al., 1976).
c.

Cholinergic Agonist and Antagonists
There is considerable evidence suggesting that

acetylcholine (ACh) may be involved in some of the acute
manifestations of morphine action and in the expression of
certain withdrawal signs.

Several investigators have indi-

cated a possible role for cholinergic mechanisms in the withdrawal syndrome precipi tated by narcotic antagonists.

The

changes in the jumping response appear to be related to brain
levels of acetylcholine.

It has been demonstrated the mor-

phine dependent animals which jump after a naloxone injection
exhibited a decrease in brain acetylcholine, whereas those
that did not jump exhibited no change in brain acetylcholine
(Bhargava and Way, 1975).

Elevation of brain acetylcholine

by the cholinesterase inhibitor physost i gmine greatly inhibit
naloxone-precipitated withdrawal jumping in mice (Bhargava
and Way, 1972; 1976; Brase et al., 1974). Conversely, injection of hemicholinium intracerebrally to inhibit central
nervous system acetylcholine synthesis, enhanced naloxoneprecipitated withdrawal jumping (Bhargava and Way, 1976).
The centrally active cholinergic agonist nicotine, tremorine,
oxotremorine and arecoline have been found to significantly
inhibit naloxone induced jumping behavior i n mice (Brase et
al., 1974).

Whereas the cholinergic antagonist atropine,

benztropine, pempidine and mecamylamine significantly
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potentiate this jumping (Brase et al., 1974).

However the

effects elicited by the cholinergic antagonist atropine on
precipitated withdrawal conflict since both an enhancement
and an inhibition of naloxone-precipitated withdrawal jumping have been found. The critical factors in whether a
stimulatory or inhibitory response is to be elicited by
atropine appears to be the time of atropine administration
and the brain level of acetylcholine. When naloxone is administered 10 min after atropine there is enhanced jumping
response (Brase et al., 1974; Bhargava and Way, 1976).

How-

ever, if naloxone is administered 30 min after atropine the
jumping response is inhibited and after 2 hours no effect
of atropine is apparent (Jhamandas and Dickinson, 1973;
Iwamoto et al., 1973).

During peak naloxone-precipitated

withdrawal jumping there is a lowering of brain acetylcholine
(Bhargava and Way, 1975).

When atropine enhances naloxone

precipitated withdrawal jumping, brain acetylcholine levels
are also decreased.

At those time intervals when the poten-

tiating action of atropine is absent, brain acetylcholine
levels are normal {Bhargava and Way, 1976).
Several studies exist which have examined the effects
of cholinergic and anticholinergic agents on the expression
of morphine dependence in rats {Frederickson and Pinsky,
1975; Hynes et al., 1976). The anticholinergic drugs atropine and mecomylamine were found to have a biphasic effect
on the narcotic withdrawal syndrome by Frederickson and
Pinsky {1975).

Mecamylamine by itself potentiated the peak
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severity and accelerated the subsequent decline in severity
of the signs.

Atropine by itself was found to have a simi-

lar tendency but none of its effects proved significant
(Frederickson and Pinsky, 1975).

However, when the two

treatments were combined, there was no significant effect on
the severity of withdrawal

(Frederickson and Pinsky, 1975).

Apparently the action of atropine antagonized the actions of
mecamylamine.

Atropine methylnitrate, a peripherally active

anticholinergic, reduced the withdrawal severity (Frederickson and Pinsky, 1975).

The anticholinergic atropine and

dexetimide produced no significant effect on withdrawal wet
shakes, weight loss, piloerection and diarrhea; however,
there was a slight increase in the number of withdrawal body
shakes (Hynes et al., 1976).

Eserine sulfate, a tertiary

anticholinesterase agent, when administered during the abstinence period was found to have little effect on the severity of the total withdrawal syndrome but decreased weight
loss (Frederickson and Pinsky, 1975).

Choline chloride was

found to effectively reduce the overall withdrawal severity
and weight loss throughout the withdrawal period (Frederickson and Pinsky, 1975).

Hynes et al.

(1976) found that pilo-

carpine, a drug which stimulates cholinergic receptors, was
effective in reducing both wet dog-like body shakes and withdrawal aggression but increased diarrhea and body weight
loss.

Pretreatment with atropine blocked all of the effects

of pilocarpine on withdrawal signs.

While methylscopolamine,

an anticholinergic drug unable to penetrate into the central
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nervous system failed to block the pilocarpine-induced inhibition of withdrawal wet shakes but protected the animal
against pilocarpine-induced diarrhea, suggesting that pilocarpine 's reduction of withdrawal body shakes was centrally
mediated (Hynes et al., 1976).

The hyperinitabil i ty charac-

teristics of the abstinence syndrome have been attenuated by
the administration of the physostigmine (Grumbach, 1969).
Atropine and methylatropine have been also tested in
rats for their ability to alter the reinforcing action of
intravenous morphine sulfate.

Morphine self-administration

was blocked by atropine but not by methylatropine (Davis and
Smith, 1975).

Similarly, atropine but not methylatropine

prevented the establishment of a conditioned reinforcer based
on passive intravenous infusions of morphine (Davis and
Smith, 1975).

These results indicate that a central cholin-

ergic system exerts an influence on the brain mechanisms
which are affected by morphine to produce positive reinforcement (Davis and Smith, 1975).
d.

5-Hydroxytryptamine Agonist and Antagonist
Evidence suggesting that morphine and 5-hydroxy-

tryptomine (5-HT) may interact in the peripheral and central
nervous systems is mostly circumstantial.

Molecular models

of morphine exhibit some degree of complementariness to 5-HT
and arguments can be made indicating that certain actions of
morphine may be mediated by endogenous 5-HT.

The compound,

p-chlorophenylalanine (PCPA), which selectively inhibits the
synthesis of 5-HT (Koe and Weissman, 1966) has been reported

23

to modify morphine effects on analgesia (Tenen, 1968; Fennessy
and Lee, 1970) and on motor activity (Eidelberg and Schwartz,
1970; Cheney and Goldstein, 1971) .

Attempts have been made

to modify the morphine abstinence syndrome with agents that
might alter brain 5-HT, but no clear picture has emerged.
Cyproheptadine, a 5-HT antagonist, when given in large doses
prior to levallorphan precipitated withdrawal abolished teeth
chattering, ej a culations, wet dog shakes, loose stools and
reduced body weight loss (Opitz and Reimann, 1973).

Huidobro

et al., (1963) re ported that the administration of 5-HT or its
metabolic precursors attenuated the abstinence syndrome.
Collier (1965) in the development of his receptor theory of
tolerance and depe ndence, pointed out that the abstinence
signs in the dog a n d rat are very similar to those produced
by the administration of the 5-HT precursor, 5-hydroxytryptophan.
Several attempts to link morphine with 5-HT in the
tolerant and dependent state have been made by studying the
effects of morphine on brain concentrations of 5-HT after
repeated morphine administra tion and during the withdrawal
state.

The evidence indicates that steady state levels of

5-HT are affected only slightly, or not at all, by acute or
chronic morphine administration or by morphine withdrawal
(Way, 1971; Way and Shen, 1971).

A comparison of the turn-

over of brain 5-HT in tolerant and non-tolerant mice revealed a mean increase in tolerant animals more than double
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that in non-tolerant ones (Way, Loh and Shen, 1968; Loh, Shen
and Way, 1969; Shen, Loh and Way, 1970).

The increased rate

of 5-HT synthesis resulting from chronic morphine administration was blocked by cycloheximide, an inhibitor of protein
synthesis and this was accompanied by an inhibition of tolerance and development of physical dependence to morphine
(Way et al., 1968; Loh et al., 1969). When the development of
tolerance and physical dependence to morphine was prevented
by concomitant administration of the narcotic antagonist,
naloxone, the increased brain 5-HT levels was also prevented.
The elevated turnover rate which existed during the tolerant
state reverted to normal two -weeks after withdrawal
et al., 1969).

(Loh

When brain 5-HT synthesis was inhibited by

PCPA, tolerance and physical dependence development to morphine was in part prevented (Way et al., 1968; Shen et al.,
1970).

On the basis of these findings it has been suggested

that 5-HT turnover may be associated with morphine tolerance
and physical dependence .
e.

Endorphins
Intracerebroventricular administration of meth-

ionine-enkephalin or morphine sulfate prior to naloxone administration has been shown to inhibit the precipitated withdrawal jumping response in mice dependent on morphine by
the pellet implantation method (Bhargava, 1977).

Howevever,

both methionine-enkephalin and morphine sulfate failed to
inhibit withdrawal defecation and rearing behavior. Morphine
sulfate was found to be 4 times as potent as methionine-
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enkephalin, on molar basis, in inhibiting the abstinence syndrome (Bhargava, 1977).
f.

Miscellaneous Drugs
Tetrahydroconnabinol when administered prior to

naloxone precipitated abstinence in rats, blocked the appearance of wet shakes and escapes (Hine et al., 1975), and reduced withdrawal jumping, defecation and rearing in mice
(Bhargava, 1976).

C.

The Pharmacology of Naloxone
Naloxone or N-allylnoroxymorphone was synthesized by

Lewenstein and Fishman in the early part of 1960 from oxymorphone, a potent analgesic (Blumberg and Dayton, 1973).
Initial investigations demonstrated that naloxone was a potent narcotic antagonist in animals being about 10-20 times
more active than nalorphine (Blumberg et al., 1961).
lowing the animal studies, Foldes et al.

Fol-

(1963) reported

that naloxone was also a potent narcotic antagonist in man.
1.

Narcotic Antagonism
Naloxone is at least 10-20 times more active than

nalorphine and about 3-6 times more active than levallorphan
when tested by prevention of the Straub tail erection in
mice, by counteraction of narcosis in rats, and by counter
action of narcotic depression of respiration in rabbits
(Blumberg et al., 1965).

In precipitating the withdrawal

syndrome in morphine-dependent monkeys, naloxone is about 7
times more active than nalorphine (Deneau and Seevers, 1963).
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Nalorphine is a narcotic antagonist that has several undesirable side effects, such as respiratory depression and psychotomimetic reactions (Blumberg and Dayton, 1973). Similarly, naloxone is 5-8 times m:>re potent than nalorphine in
precipitating the abstinence syndrome in morphine-dependent
humans and is itself non-addicting (Jasinski et al., 1967).
Naloxone acts very rapidly and counteracts narcotic
depression within 1-2 min when given intravenously (Blumberg
and Dayton, 1973).

Peak brain levels of naloxone occur with-

in 15 min of injection and decline by 50 percent within 1
hour (Berkowitz et al., 1975).

It is effective in counter-

acting various different narcotics, but is ineffective
against non-narcotic depressants such as barbiturates
(Blumberg and Dayton, 1973).
2.

Counteraction of Narcotic Antagonist Analgesics
Unlike nalorphine and levallorphan, naloxone not

only counteracts narcotics but also counteracts agonist effects of narcotic antagonist analgesics. Thus naloxone
counteracts the depressant effects of cyclazocine on the
flexor reflex of the spinal dog (Mcclane and Martin, 1967),
the antinoriceptive activity of cyclazocine, cyclorphan,
levallorphan, nalorphine and pentazocine in writhing test
in mice and rats

(Blumberg et al., 1966).

The depressant

action of pentazocine in rats and the respiratory depression
caused by pentazocine in anaesthetized dogs are also reversed by naloxone (Blumberg and Dayton, 1973).

In man,

naloxone also counteracts undesirable side effects of
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cycloazocine (Jasinski et al., 1968) and the respiratory
depressent action of pentazocine (Kallos and Smith, 1968).
3.

Other Pharmacological Properties of Naloxone
Naloxone is not a 'pure' antagonist for at high doses

it does exhibit some agonist actions .

For example, in rats

a dose of 50 mg/kg, which is about 200 times the narcotic
antagonist dose, will produce restlessness and salivation.
At higher toxic doses clonic-tonic convulsions appear
(Blumberg and Dayton, 1973).

At doses well above the nar-

cotic antagonist dose naloxone appears to manifest few or
no side effects or agonist action in man or mammalian laboratory animals

(Blumberg and Dayton, 1973).

However, there

is some evidence of agon ist activity at non-toxic doses in
behavior experiments in pigeons (McMillan et al., 1970).
Naloxone, although a very potent narcotic antagonist,
appears to show no anti-nociceptive activity in animals
(Blumberg et al., 1961; Blumberg et al., 1965) and little or
no analgesic activity in man (Blumberg and Dayton, 1973).
There is essentially no effect on respiration at therapeutic
doses of naloxone in narcotic-free animals.

However, at

about 100 times the antagonist dose in rabbits the respiratory rate and minute volume begin to show a slight increase
(Blumberg and Dayton, 1973).

Naloxone by itself has essen-

tially no effect on respiration in man (Foldes et al., 1963;
Jasinski et al., 1967).

Heart rate and blood pressure are

not significantly affected by naloxone (Blumberg and Dayton,
1973).

Naloxone likewise has little or no cardiovascular
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effect in man (Jasinski et al., 1967). Naloxone causes no
significant change in the body temperature of rabbits or
dogs (Blumberg and Dayton, 1973).
Naloxone has been shown to modify the effects of
a-amphetamine on continuous avoidance behavior in the ra t
(Holtzman and Jewett, 1973; Holtzman, 1974).

The dose re-

sponse curves for a-amphetamine stimulation of continuous
avoidance and locomotor activity were shifted downward by
the administration of naloxone (Holtzman, 1974).

Addition-

ally, naloxone has proven to be almost as effective as
a-amphetamine in suppressing food intake in food-deprived
rats (Holtzman, 1974).

However, naloxone failed to affect

food intake in the mous e, indicating that some e ffects of
naloxone may be species dependent (Holtzman, 1974).

Nalox-

one has also been shown to block apomorphine induced sterotyped behaviors in male guinea pigs (Moon and Margolin, 1977).
Haloperidol and morphine sulfate completely suppress
bar-pressing for brain self-stimulation in rats implanted
with electrodes in the lateral hypothalamus (Wauquier et
al., 1974).

Naloxone at a dose (5 mg/kg) which was inef-

fective when given alone, differentially reversed the morphine effects but was without any reversing influence on the
actions of haloperidol (Wauquier et al., 1974).

When the

self-stimulating electrodes are in or just lateral to the
pontine central gray the rate of self-stimulation was doserelatedly decreased by naloxone administration (Belluzzi
and Stein, 1977).

Electrical stimulation of the periaque-
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ductal grey matter in rats and humans has been found to produce a strong analgesia (Mayer and Liebeskind, 1974; Akil
et al., 1976) which is antagonized by naloxone (Aki l et al.,
1976; Adams, 1976).
Several experiments have demonstrated that naloxone
can restore normal peristaltic reflex activity in fatigued
guinea pig preparations or after inhibition by adenine
nucleotides (Van Neuten et al., 1976). Distention of the
guinea pig ileum segment elicits peristaltic activity, however maintenance of this distended condition results in the
gradual disappearance of peristaltic activity (Van Neuten
et al., 1976).
al.

Naloxone has been found by Van Neuten et

(1976) to restore normal activity in such preparations.

Adenosine, adenosine monophosphate, adenosine diphosphate
and adenosine triphosphate inhibit the perestaltic reflex
activity of guinea pig ileum and this inhibitory effect is
also reversed by naloxone

(Van Neuten et al., 1976).

In

the guinea pig ileum segment, met-enkephalin, an endogenous
ligand for the opiate receptor, causes a dose-dependent inhibition of the rhythmic peristaltic reflex activity induced
by increasing the distending pressure (Van Neuten et al.,
1977). This inhibitory effect of met-enkephalin is reversed
by naloxone (Van Neuten et al., 1977).
Recent studies have revealed the existence of endogenous morphine-like compounds in the central nervous system
(Teschemacher et al., 1975; Hughes et al., 1975).

These

endogenous morphine-like compounds have been reported to
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produce analgesia when injected intraventricularly in rats
and cats (Belluzzi et al., 1976) which is antagonized by naloxone.

A morphine-like peptide obtained from the pituitary

gland, endorphin, and two brain peptides, enkephalins, have
been shown to have a high affinity for the opiate receptor
demonstrated by displacement of naloxone from these receptors
(Terenius and Wahlstrom, 1975; Pasternak et al., 1975;
Bradbury et al., 1976). These findings have led to the hypothesis that these morphine-like compounds are partially responsible for pain thresholds.

If this is true then an an-

tagonism of the effects of the endogenous compounds by naloxone should affect pain perception.

However, naloxone has

been found not to alter the perception of experimentally induced pain in normal human subjects (El-Sobky et al., 1976).
Rats treated with doses of naloxone sufficient to block morphine analgesia have been found to show no change in the
threshold for escape from foot shock (Goldstein et al., 1976).
However, naloxone has been shown to lower pain threshold in
mice (Jacob et al., 1974), to block analgesia produced by
electrical stimulation of the periaqueductal grey in rats
(Akil et al., 1976), to antagonize acupuncture analgesia in
man (Mayer and Price, 1976), and to antagonize nitrous oxide
analgesia in mice (Berkowitz et al., 1976).

Bell and Martin

(1977) recorded C-fiber reflexes from an S, ventral root in
the acute decerabrate low spinal cat following stimulation of
the ipsilateral superficial peroneal nerve or application of
radiant heat to the metacarpel footpad.

Naloxone was found
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to increase the electrically evoked C-fiber reflex and the
radiant heat evoked ventral root reflex (Bell and Martin,
1977).

The fact that naloxone facilitated these reflexes in

doses too small to have non-specific excitatory effects is
consistent with the hypothesis that these effects are due to
antagonism of a naturally occurring opiate-like substance . .

D.

Opiate Receptors
1.

Stereospecific Binding Sites for Opiates
It has been postulated for many years that opiates

must bind to macromolecular sites or receptors located in,
or on the surface of, nerve cells before they can produce
their characteristic pharmacological responses.

The reason

for this receptor postulate was the high degree of structural and steric specificity which characterizes opiate action.
Among the many classes of natural and synthetic morphinelike analgesics studied, it is usually the D-isomer that is
active, while the L enantiomorph tends to have very low or
no analgesic potency (Simon, 1976).

Small structural alter-

ations in the opiate molecule can lead to dramatic changes
in potency.

The search for opiate receptors has been under-

way in a number of laboratories for many years.
success was limited until Goldstein et al.

However,

(1971) suggested

using stereospecificity as a criterion of receptor binding.
3
They incubated mouse brain homogenate with H -levorphanol.
Stereospecif ic binding was defined as that portion of the
binding that was prevented b y levorphanol but not by
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dextrorphan.

In their experiments stereospecific binding

amounted to only 2% of total binding.

Using modifications of

the Goldstein procedure Pert and Snyder (1973), Simon and his
co-workers

(1973) and Terenius (1973a) independently identi-

fied binding to brain tissue that was highly stereospecif ic
by using labeled opiates and opiate antagonist of high specific activity.
Stereospecific binding sites have been found in the
central nervous system of many species and the myenteric
plexus of the guinea pig ileum. They are tightly bound to
membranous elements of the cell and have been reported to
be most concentrated in the synaptosomal fraction of brain
and guinea pig ileum homogenates (Hitzeman et al., 1974; Pert
et al., 1974; Terenius, 1973b) suggesting that they occur on
membranes in the vicinity of synapses.

Whether they are situ-

ated pre- or postsynaptically has not yet been established.
Opiate binding sites have been found in the central nervous
system of every vertebrate species so far examined, including
man (Hiller et al., 1973) but not in that of any invertebrates (Pert et al., 1974).
Biochemical studies have shown that stereospecific
binding of opiates is highly sensitive to proteolytic enzymes
(Simon et al., 1973; Pasternak and Snyder, 1973) and various
sulfhydryl reagents (Simon et al., 1973; Terenius, 1973a)
suggesting the participation of protein.

The binding of

agonist and antagonist drugs has a broad pH optimum between
6.5 and 8, and is decreased by the presence of alkali,
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alkaline earth, transition metal and organic cations.

An ex-

ception is the sodium ion which at concentrations up to 200
mM enhances antagonist binding while depressing agonist bind-

ing (Simon, 1976).
Opiate binding sites have high affinity for narcotic
analgesics and their antagonists. Dissociation constants
range from 0.4 nM for etorphine to no detectable affinity for
drugs which do not exhibit morphine-like narcotic analgesic
effects (Simon, 1976).

One of the most important convincing

pieces of evidence regarding the pharmacological relevance
of binding sites is the degree of correlation between binding affinity of a variety of ligands and their pharmacological potency.

Excellent correlation has been found between

the in vivo potencies of opiates and antagonists and their
affinities for the stereospecific binding sites in vitro
(Simon et al., 1973; Pert and Snyder, 1973; Terenius, 1974).
The ability of opiates to inhibit electrically stimulated
contractions of the isolated guinea pig ileum has also been
shown to be very well correlated with their binding affinities for stereospecific sites in the myenteric plexus of
the ileum (Creese and Snyder, 1975).

Narcotic binding af-

finities, determined both in the presence and absence of
sodium, showed excellent and closely similar correlation
with the tail withdrawal analgesia test in rats after intravenous administration of drugs (Simon, 1976).

Very high

correlation was also obtained between binding affinities of
drugs and their ability to inhibit the contractions of the
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guinea pig ileum. These binding affinities show good correlation with the cod-liver oil test for antidiarrheal potency
(Simon, 1976).

The stereospecificity, saturability and high

affinity of the stereospecific opiate binding sites and the
excellent correlation between pote ncy and binding affinity of
opiates and their antagonist strongly support the hypothesis
that these sites are pharmacologically relevant recognition
and binding sites for opiates.
a.

Distribution of Opiate Receptors in Different

Regions of the Brain
The manner in which stereospecific binding sites
are distributed throughout the brain is of considerable interest as a clue to the sites of opiate action. Receptor
binding has been determined in numerous regions of the monkey
brain where receptor binding varies by a greater than 30-fold
range (Kuhar et al., 1973).

The amygdala shows the greatest

amount of receptor binding, with its anterior portion displaying almost twice as much as the posterior. Binding in the
periaqueductal area of the midbrain is about the same as in
the posterior amygdala. The hypothalamus and med ial thalamus,
the next highest areas, display only about 40 percent as much
binding as the anterior amygdala.

In the head of the caudate,

receptor binding has been found to be 80 percent of that in
the hypothalamus and medial thalamus.

Marked regional varia-

tions have also been found within the cerebral cortex. Frontal
cortex is the highest cortical area with precentral gyrus,
postcentral gyrus and occipital pole showing considerably
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less binding.

Receptor binding is very low or not detectable

in various white matter areas.

The cerebellum, lower brain

stem and the spinal cord show only very low levels of receptor binding (Kuhar et al., 1973).

Stereospecific binding

has also been demonstrated in human brain (Hiller et al.,
1973).

There are large differences in binding within the hu-

man brain ranging from 0.4 pmol/mg protein in the olfactory
trigone, amygdala and septal nuclei to virtually no binding
in cerebral white matter, dentate nucleus of the cerebellum,
tegmentum, pineal and pituitary gland (Simon, 1976; Hiller,
1973).

The most interesting conclusions reached from these

studies is that most areas with high opiate binding are located in, or associated with, the limbic system.
The heterogenity of opiate receptor distribution is
reminiscent of the large regional differences observed for
concentrations of the neurotransmitters.

There are similar-

ities of opiate receptor distribution to the distribution
of several neurotransmitters, such as acetylcholine,d'l -aminobutyric acid, serotonin and the catecholamines (Snyder and
Pert, 1975).

However, there are some differences as well.

Acetylcholine and opiate receptor binding are both high in
the caudate nucleus, the putamen is quite rich in acetylcholine but contains only a moderate degree of opiate binding.

The periaqueductal areas of the midbrain, which pos-

sesses the second highest levels of opiate receptors, has
only moderate acetylcholine-synthesizing capacity (Snyder and
Pert, 1975).

Whereas the hypothalamus is rich in both
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d"aminobutyric acid and opiate receptors, the globus pallidus
which contains one of the highest

r

-aminobutyric acid con-

centrations in the brain, is relatively low in opiate receptor
binding (Snyder and Pert, 1975).

The caudate nucleus is high

in opiate receptor binding and tyrosine hydroxylase, the rate
limiting enzyme in catecholamine synthesis.

Additionally,

the hypothalamus and periaqueductal gray are also rich in tyrosine hydroxylase and opiate receptor binding.

However, while

the medial thalamus contains much more opiate receptor binding
than the lateral hypothalamus,the reverse is true for tyrosine
hydroxylase (Snyder and Pert, 1975).

Serotonin is found in

the caudate, hypothalamus and amygdala just as the opiate receptor is.

However the midbrain raphe area, which contains

the cell bodies of serotonin neurons in the brain and one of
the richest in serotonin content, is quite low in opiate receptor binding (Snyder and Pert, 1975).

Lesions that selec-

tively destroy norepinephrine, serotonin, acetylcholine, or
dopamine containing pathways have no effect on opiate receptor binding in the areas of brain in which these pathways
possess the greatest density of nerve terminals (Kuhar et
al., 1973).

These results indicate that the opiate receptors

are not localized on or within the nerve terminals of the
specific neurotransmitter pathways discussed here.
b.

Interaction of Opiate Receptors with Agonist and

Antagonist
Simon et al.

(1973) reported that the presence

of salt in the incubation mixture led to a dose-dependent
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decrease in etorphine binding while no such effect was observed for naloxone binding by Pert and Snyder (1973).

The

effect of salt is a general one between the classes of agonist and antagonist drugs resulting in an actual enhancement
of antagonist binding which in the case of naloxone and naltrexone is at least two-fold (Pert and Snyder, 1974).

They

have further demonstrated that the effect is not a salt or
ionic strength effect but a unique property of sodium ions,
exhibited to a lesser extent by lithium but by none of the
other alkali metal ions.

None of a large variety of other

cations studied including alkaline earth and transition
metals (Pert and Snyder, 1974) nor a series of organic cations

(Simon et al., 1975) could mimic the selective action

of sodium and lithium.

This effect is remarkable both for

the ability of an inorganic cation to distinguish between
such close related structures as opiate agonist and antagonists and for the uniqueness of sodium in this regard.
The question of whether the changes produced by sodium
are due to changes in the number of binding sites or in binding affinities has been explored by both the Simon and Snyder
groups.

However, on this point there exists disagreement be-

tween the experiments performed in the two laboratories which
has yet to be resolved.

Pert and Snyder (1974) have reported

an increase in the number of high affinity bindin g sites for
naloxone in the presence of sodium with no change in affinity.
On the other hand, Simon et al.

(1975) reported that sodium

causes an increase in the affinity of naltrexone without any
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change in the number of binding sites.
binding Simon et al.

Similarly, for agonist

(1975) reported a decrease in affinity

while Pert and Snyder (1974) reported a decrease in number of
binding sites.
Unlabeled opiates have been allowed to compete with
labeled antagonists in the presence and absence of sodium.
When the unlabeled competitor was a relatively poor antagonist there was little or no change in the concentration able
to displace 50 percent of the labeled antagonist (ED 50 ) in
the presence of sodium while the ED

50

increased dramatically (Simon, 1976).

of strong agonist was
Drugs with mixed

agonist-antagonist properties acted in an intermediate fashion, their ED
one.

50

for displacement of 3H-naloxone or 3H-nalt:r€x-

being increased 2 to 7 fold in sodium (Simon, 1976).

Shifts in ED 50 are compatible with changes in affinity but
not with changes in the number of binding sites (Simon, 1976).
In spite of the disparity of results between the Simon
and Snyder groups they view the mechanism of the sodium effect in a similar manner and have independently proposed
similar models

(Simon, 1975; Pert and Snyder, 1975).

The

essence of these models is that the sodium ion acts as an
allosteric effector, the binding of which to an allosteric
site on the receptor molecule results in a conformational
change in the opiate binding site.

The new conformer, so-

dium dependent, exhibits a higher affinity for antagonist
and a lower affinity for agonist than the conformer that
exists in sodium-free media.
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c.

The Effect of Tolerance and Dependence on Opiate

Receptors
There has been great interest in the way the development of tolerance and physical dependence may affect
the number and properties of opiate receptors.

It has been

known for a long time that during chronic morphinization
there is not only an increase in the dose of morphine required
to produce analgesia and other central effect (tolerance) but
there is also a dramatic decrease in the amount of antagonist
required to produce precipitated withdrawal.

Thus it is

attractive to postulate that these changes result from alterations in the receptor which increase its affinity for antagonists and reduce its affinity for agonists (Simon, 1976).
To date experiments in several laboratories have failed to
provide direct evidence for either a qualitative or quantitative change in opiate receptors during chronic treatment of
animals with opiates.

Klee and Streaty (1974) reported that

the binding of 3 H-dihydromorphine to particulate fractions
derived from the brains of controls and morphine dependent
rats is identical with respect to both number of sites and
binding affinity.

The displacement of bound dihydromorphine

by either morphine or naloxone is unchanged in brain fractions from dependent rats

(Klee and Streaty, 1974).

The

latter results provides evidence against a significant increase in the affinity of antagonist.

Similar negative re-

sults have been obtained by Hitzeman et al.
et al.

(1973).

(1974) and Pert
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2.

The Binding of Non-Narcotic Drugs to the Opiate

Receptor Site
a.

Butyrophenone Influences and Related Neuroleptics
The butyrophenones, neuroleptic drug useful in

the treatment of schizophrenia, were developed as analogues
of the opiate meperidine (Janssen, 1965). Recently, haloperidol, the prototype of the butyrophenones, was found to bind
to the opiate receptor and inhibit binding of labeled naloxone (Clay and Brougham, 1975).

The haloperidol binding is

greatly reduced in the presence of 100 nM Na

+

(Clay and

Brougham, 1975), and this finding is consistent with the data
reported for other opiate agonists (Pert and Snyder, 1974).
However, the affinity of haloperidol for the opiate receptor
is markedly different from that of morphine. Clay and Brougham
(1975) found that the concentration of morphine required t o
3
reduce the stereospecific binding of 8 nM [ H]-naloxone by 50

percent was 12 nM while the concentration of haloperidol
needed to achieve the same effect was 880 nM.

Although both

morphine and haloperidol are bound in a competitive manner to
the opiate receptor, there is some indication that haloperidol may be bound in a different manner than morphine.

This

indication is provided by an analysis of the log-probit plots
for the binding affinity of these drugs.

Morphine has a pro-

file that parallels that of a large number of opiate agonist
and antagonists
1973).

(Clay and Brougham, 1975; Pert and Sny der,

Haloperidol appears to have a binding profile differ-

ing from that reported for morphine o r other opiate agonist

41

and antagonists (Clay and Brougham, 1975).
been confirmed by Creese et al.

These results have

(1976) who have also shown

that several other butyrophenones also display substantial
potency as inhibitors of 3H naloxone binding.

They have found

benperidol and pimozide to be almost as potent as the opiate
fentanyl in inhibiting 3 H-naloxone binding in the presence of
sodium. The potency of these two drugs is decreased very
little in the presence of sodium, suggesting that these pharmacological actions may resemble those of opiate antagonist
(Pert et al., 1973; Pert and Snyder, 1974).

On the other

hand, spiperone was found to lose a great deal of potency in
the presence of sodium, consistent with opiate agonist activity.

The other butyrophenones tested by Creese et al.

(1976)

respond to sodium in a fashion resembling that of mixed
agonist-antagonists.
The results achieved by Creese et al.

(19 76) for pimo-

zide differ from those of Clay and Brougham (1975) who found
pimozide to have no effect on opiate binding.

Other studies

have also shown pimozide to have no significant effect on
the specific binding of the tritiated opiate antagonist,
naloxone (Charalampous and Askew, 1974).
have influences on the opiate receptor.

Phenothiazine also
Creese et al.

(1976),

have fo.und that a number of the phenoth i az i ne neuroleptics
also inhibit 3H-naloxone binding.

Of the phenothiazines

tested, thioridazine was the most potent wi th promethazine
(a non-neuroleptic phenothiazine) and chlorpromazine being
somewhat weaker.

Fluphenazine, one of the most potent
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neuroleptic phenothiazines, is one of the weakest in its influence on the opiate receptor binding of 3H-naloxone (Creese
et al., 1976).

However, other investigators have found

chlorpromazine to not affect opiate binding at concentrations
up to 10- 3 M (Clay and Brougham, 1975).

Sodium decreases

the potency of thioridozine by 1.5 fold, consistent with an
opiate antagonist profile, while the sodium ratio for the
other phenothiazines resemble opiate mixed agonist-antagonists
(Creese et al., 1976).

In light of the fact that these drugs

have a very low affinity for the opiate receptor, this suggests that the sodium influences for these drugs do not have
major pharmacological relevance.
b.

Adrenergic Agents
Phenoxybenzamine, an alpha receptor antagonist,

has been found to have no significant effect on the binding
of naloxone (Charalampous and Askew, 1974).

However, the

beta adrenergic receptor antagonist, propanolol and the
beta adrenergic agonist, isoproterenol, were found to significantly reduce the binding of naloxone to the opiate receptor (Charalampous and Askew, 1974).

The inhibition of

binding by propanolol was reconfirmed by in vivo administration of propanolol.

Sodium was found not to affect binding

of the beta antagonist and agonist as with specific opiate
antagonists and agonists
c.

(Charalampous and Askew, 1974).

Cholinergic Agents
Atropine, a muscarinic cholinergic receptor an-

tagonist, was found to not significantly affect specific

43

binding of the triated opiate antagonist, naloxone (Charalampous and Askew, 1974; Pert and Snyder, 1973).

E.

A Comparison of Narcotic Analgesics with Neuroleptics
Narcotic analgesics bear certain behavioral and bio-

chemical similarities to neuroleptic drugs.
1.

Behavioral Similarities
a.

Acute Actions
(1)

Catalepsy
Catalepsy is a state of behavioral immo-

bility accompanied by either muscular hypotonia as with neuroleptics, or by muscle rigidity as with narcotics.

Both, halo-

peridol and morphine, cause catalepsy in zoost animal species
and in human subjects, with the Eo
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kg, respectively (Lal et al., 1975).

in rats, 1.5 and 20 umol/
The catalepsy induced

either by haloperidol or by morphine has been effectively
counteracted by apomorphine as benztropine (Lal et al., 1975).
B-Endorphin, an endogenous peptide with morphine-like biological properties, has been found to also produce catalepsy
when injected into the periaqueductal gray (Jacquet and
Marks, 1976) and the cerebrospinal fluid (Bloom et al., 1976).
(2)

Jumping
Dihydroxyphenylalanine (L-DOPA) injected

in mice pretreated with amphetamine reliably elicits upward
jumping (Lal, et al., 1975a).

Haloperidol, pimozide, chlor-

promazine, thionidazine and clozapine block the mouse jumping (Colpaer et al., 1975) suggesting that jumping behavior
is a measure of dopaminergic stimulation.

Morphine also
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blocks mouse jumping in a dose related manner (Lal et al.,
1975a).

Dexitimide, a centrally acting anticholinergic drug,

reversed the pimozide induced blockade of jumping (Van Neuten,
1962) without reversing the morphine induced blockade (Lal
et al., 1975), suggesting that the narcotics block dopamine
receptors but through a different brain site which does not
involve a doparninergic cholinergic interaction (Lal et al.,
1975).
(3)

Stereotypy
Drugs which directly or indirectly stimu-

late dopamine receptors cause stereotypy in rats.

Morphine,

methadone and demerol are potent antagonists of apomorphine
and amphetamine in the stereotypy test.

Amphetamine and apo-

morphine induced stereotypies are also antagonized by neuroleptic drugs (Lal et al., 1975).
(4)

Vomiting
The narcotic drugs, morphine, methadone

and demerol are potent antagonist of apomorphine induced
vomiting in dogs

(Lal et al., 1975).

Neuroleptics also show

marked activity in antagonizing apomorphine induced vomiting
(Lal et al . , 19 7 5) •
( 5)

Aggression
Aggression can be elicited in laboratory

animals by a variety of treatments.

Apomorphine produces

aggression in a dose dependent manner and both haloperidol
and morphine effectively block this aggression (Lal et al.,
1975).

Additionally, haloperidol and morphine effectively
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block the aggression elicited by amphetamine and L-DOPA treatment (Lal et al., 1975).

Electric shock delivered to the paw

is known to elicit aggression in paired rats.

Haloperidol

and morphine block shock induced aggression in a dose-dependent manner ·: (Lal et al., 1975).

Withdrawal from narcotic drugs

produces marked irritability and aggression (Lal, 1975).

This

withdrawal aggression is blocked by narcotics and neuroleptics in relatively low doses (Puri and Lal, 1973).
(6)

Neuroleptanalgesia
Various combinations of narcotic analgesics

and butyrophenones have been employed for neuroleptanalgesia
as a total or partial alternative to surgical anesthesia (De
Castro and Mundeleer, 1959; Nilson and Janssen, 1961; Deligene,
1961; Edmonds-Seal and Prys-Roberts, 1970; Lewis and Jennings,
1972).

The term neuroleptanalgesia implies the use of a

butyrophenone in combination with a short-acting, potent analgesic (Edmonds-Seal and Prys-Roberts, 1970).

Of the buty-

rophenones available those commonly used in neuroleptanalgesia
are haloperidol and droperidol.

The analgesics commonly used

in neuroleptanalgesia are dextromorarnide (Palfiurn), phenoperidine (Operidine) and fentanyl

(Sublimaze) in order of in-

creasing potency and decreasing duration of action (EdrnondsSeal and Prys-Roberts, 1970).
The effects of mixtures of neuroleptics and analgesic
drugs may be predicted from a knowledge of the pharmacology
of the constituents.

The pharmacology of the mixture of

fentanyl citrate and droperidol

(Innovan) will be examined
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since it is the most common of the neuroleptanalgesics.

Drop-

eridol is a butyrophenone type neuroleptic which produces
sedation, tranquilization, adrenergic blockade and vasodilation (Janssen et al., 1963; Yelnosky et al., 1964), whereas
studies on the pharmacology of fentanyl citrate alone indicate
its principal actions are analgesia, central nervrussystem
depression, respiratory depression and bradycardia (Janssen,
1962; Gardocki and Yelnosky, 1964).

Each compound in the

mixture exerts its own pharmacologic action without any welldefined antagonistic or potentiating interactions with one
exception.

Droperidol enhances the analgesic activity of

fentanyl citrate (Yelnosky and Gardocki, 1964).

Since droper-

idol appears to be devoid of analgesic activity, the enhancement of the analgesic action of fentanyl citrate is the result of a potentiating effect of droperidol, not an additive
effect.

The mechanism of potentiation is not known; however,

i t is doubtful that i t is due to inference by droperidol
with the catabolism of fentanyl citrate since the duration
of analgesic action of the combination was no greater than
that of fentanyl alone (Yelnosky and Gardocki, 1964). Other
investigators have found no potentiation of the analgesic
effect of fentanyl by droperidol (Corssen, Domino and Sweet,
1964; Prys-Roberts and Kelnan, 1967).

The neuroleptics do not

appear to augment the ventilatory depressant effects of the
analgesics (Corssen, Domino and Sweet, 1964; Yelnosky and
Gardocki, 1964; Prys-Roberts and Kelman, 1967; Harper et al.,
1976).

Nausea and vomiting have been found after the
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administration of fentanyl

(Harper et al., 1976).

This is

hardly surprising since this result occurs with most narcotics.
However, the concomitant administration of droperidol reduced
the incidence of nausea and vomiting (Harper et al., 1976).
Fentanyl produces minimal circulatory changes as evidenced by
the lack of orthostatic hypotension (Harper et al., 1976).
This is in contrast to the combination of fentanyl plus droperidol which appears to predispose some patients to orthostatic hypotension (Harper et al., 1976).

The hyperthermia

normally seen after morphine administration in cats has been
reported to be markedly potentiated by pimozide, a specific
dopamine receptor blocker (French et al., 1976).
In the state of neuroleptanalgesia the patient appears
calm, detached from his surroundings and immobile.

The face

is wit hout expression and the closed eyes give an impression
of sleep, though the patient will respond immediately to
quiet command (Hayward-Butt, 1957; Edmonds-Seal and PrysRoberts, 1970).

The degree of analgesia is dose-dependent

but limited by ventilatory depression although sufficient
analgesia can be obtained with s pontaneous vent i lation for
minor surgery (Edmonds-Seal and Prys-Roberts, 1970).
Neuroleptana lgesia has been mainly employed in minor
surgical procedures, as an adjunct to local analgesics, as
preanesthesia medication and in combination with light general anesthesia. Minor surgical procedures such as insertion
of eyelid sutures, nerve blocking injections and dressing of
burns have been performed under neuroleptanalgesia
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(Edmonds-Seal and Prys-Roberts, 1970).

Neuroleptanalgesia

combinations have been found useful for supplementing local
analgesic techniques such as retie-ocular block (Cameron,
1967), endobronchial intubation (Coppen and Fox, 1968), and
bronchoscopy procedures (Berenyi et al., 1966).

Neurolepti-

analgesia is widely used as a preanesthetic medication.
Fentanyl plus droperidol has been found to produce better
pre-operative sedation than morphine, together with significantly less post-operative nausea and vomiting (Norris and
Telfer, 1968).

The concept of combining neuroleptanalgesics

with light general anesthesia has been employed for a number
of years.

'
A mixture of fentanyl citrate and droperidol
has

been used successfully with nitrous oxide for general anesthesia in man (Holderness et al., 1963).

In the field of

cardiovascular surgery, the use of neuroleptanalgesic combination during cardiopulmonary bypass has supplanted the
use of volatile anesthetic agents which are known to depress
myocardial function (Corssen et al., 1965).
The combination of fentanyl plus droperidol has also
been used with remarkable success in dogs (Yelnosky and
William, 1964), guinea pigs (Lewis and Jennings, 1972), rats
(Jones and Simmons, 1968; Garcia et al., 1975), mice (Lewis
and Jennings, 1972), parakeets (Yelnosky and William, 1964),
and rabbits (Lewis and Jennings, 1972) to produce analgesia,
anesthesia, sediation and tranquilization for surgery.
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b.

Chronic Actions
(1)

Tolerance to Cataleptic Action
Rats made tolerant to the effects of mor-

phine by chronic treatment show tolerance to the catalepsyinducing action of both morphine and haloperidol {Lal et al.,

1975).

However, rats chronically treated with haloperidol

show no tolerance to either morphine or haloperidol {Lal et
al., 1975).
(2)

Withdrawal Signs
Withdrawal from chronic morphine produces

wet-dog-like body shakes, ptosis, weight loss, hyperactivity
and aggression {Lal, 1975).

Rats withdrawn from chronic halo-

peridol exhibit body shakes and increased locomotor activity
{Lal et al., 1975).

In both cases, the aggression eliciting

effects of apomorphine are markedly increased.

However, ad-

ministration of amphetamine to morphine-withdrawn rats elicits intense aggression {Lal et al., 1971) but fails to
elicit aggression in haloperidol withdrawn rats {Lal et al.,

1975).
2.

Biochemical Similarities
a.

Acute Actions
(1)

Striatal Dopamine
Steady state concentrations of dopamine in

the rat striaturn have been found not to change after the injection of morphine sulfate or haloperidol.

However, both

morphine and haloperidol increase the rate of dopamine depletion after inhibition of its synthesis by alpha methyl-
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paratyrosine (Lal

et al., 1976).

In the absence of changes

in dopamine steady state levels, an alteration in the depletion rates of neurotransmitter can be considered as a measure
of changes in the turnover rate of that transmitter (Co s ta
and Neff, 1966).

Both morphine and haloperidol produce a

dose-dependent increase in striatal dopamine turnover, with
haloperidol showing considerabl e more potency (Lal

et al.,

1976). The fact that both of these drugs produce increases
in striatal dopamine turnover is indicated by the fact that
they also increase striatal homovanillic acid, a dopamine
metabolite (Lal

et al., 1976).

Naloxone block the action

of morphine on striatal dopamine turnover; however, it did
not affect the similar action of haloperidol.
The effects of morphine and haloperidol in causing
stimulation of dopamine turnover coincides with their effect
on catalepsy.

Both morphine and haloperidol produce a dose-

related catalepsy (Lal et al., 1975), with the cataleptic action of morphine being readily reversed by naloxone; however,
naloxone treatment was ineffective in haloperidol catalepsy
(Wauquier et al., 1974).
An important interaction between haloperidol and morphine in producing an elevation of dopamine turnover was
noted when a subthreshold dose of haloperidol was combined
with the ED
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dose of morphine .

The subthreshold dose of

haloperidol caused a significant increase in the effect of
morphine so that the morphine ED 50 produc e d as great an effect as was produced by the maximally-effective dose of
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morphine and haloperidol were combined there was an increase
in striatal dopamine turnover equivalent to that which was
obtained by haloperidol alone (Lal, et al., 1976).
Apomorphine is known to directly stimulate dopamine
receptors (Anden et al., 1967, Ernst, 1967; Costall and Naylor,
1973) and thereby reduce dopamine turnover.

Lal et al.,

(1976) reasoned that if the actions of morphine and haloperidol involved blockade of dopamine receptors, then apomorphine
might reverse the actions of both drugs by stimulating the
same receptor.

Similarly, it has been known for some time

that anticholinergic type anti-Parkinsonian drugs interact
with dopamine containing neurons in the central nervous system and thereby alter the activity of neuroleptics.

There-

fore, if certain actions of morphine overlap with those of
haloperidol then benztropine may interact with both drugs
in a similar manner. Treatment with morphine or haloperidol
produces a significant increase in striatal dopamine turnover while apomorphine or

benztropine reduce dopamine turn-

over (Lal, et al., 1975).

Apomorphine on benztropine re-

versed the elevation of dopamine turnover elicited b y an
injection of morphine or haloperidol (Lal et al., 1976). A
similar interaction was also observed for catalepsy.

While

neither apomorphine or benztropine cause catalepsy on their
own, either drug effectively antagonized the catalepsy induced by haloperidol or morphine (Lal, et al., 1976).
The haloperidol-induced elevation of striatal dopamine turnover is markedly diminished after lesioning of the
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nigrostriatal tract at the level of the lateral hypothalamus
(Anden et al., 1973).

For purposes of comparison the nigro-

striatal tract was lesioned before the administration of morphine sulfate.

Unilateral lesions of the nigrostriatal tract

increased the dopamine content of the striaturn (Hynes et al.,
1975; Lal, et al., 1976).

Following lesioning morphine still

elevated dopamine turnover but the magnitude of this elevation was smaller than that on the intact side (Lal, et al.,
1976).

The effect of morphine on striatal dopamine turnover

was completely eliminated by bilateral lesioning of the nigrostriatal tract (Lal et al., 1976).
(2)

Adenylate Cyclase and Phosphodiesterase
Earlier studies have suggested that many

actions of the catecholamines may be mediated by cyclic AMP
(Greengard and Kebabian, 1974).

An adenylate cyclase acti-

vated by low concentrations of dopamine have been found in
homogenates of rat cuadate nucleus.

This enzyme is stimulated

by dopamine and 1-norepinephrine and in the presence of optimal amounts of either dopamine or norepinephrine no further
increase in adenylate cyclase activity can be obtained by
the addition of the other catecholamine (Krugger et al., 1975).
Like dopamine and norepinephrine, morphine sulfate added to
the homogenate of the rat striaturn also increased the formation of cyclic AMP (Lal et al., 1975; Puri et al., 1975). However, the m::>rphine stimulation of adenylate cyclase was not
antagonized by naloxone.

The maximal stimulation of adenyl-

ate cyclase by either morphine or dopamine was about the same
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(Puri et al., 1975).

When submaximally effective concentra-

tions of dopamine were combined with morphine, there was an
additive effect.

However, in the presence of an optimal

concentration of either dopamine or morphine, no further increase in adenylate cyclase activity could be obtained by
the addition of the other agent (Lal et al., 1976).
The effect of morphine on striatal phosphodiesterase
activity in crude striatal homogenates has also been measured.

The in vitro addition of morphine inhibited phospho-

diesterase activity only when the highest concentrations of
C AMP were employed.

Similarly, the in vivo administration

of morphine also inhibited phosphodiesterase activity when
the three highest C AMP concentrations were employed as substrate (Lal, et al., 1976).
b.

Chronic Actions
(1)

Striatal Dopamine
Unlike its effects in naive rats an acute

injection of morphine failed to produce an increase in the
striatal dopamine turnover in morphine-dependent rats.

In

these morphine dependent rats, dopamine turnover was markedly lower in response to an acute morphine injection than the
turnover rate obtained in naive or chronically haloperidol
treated rats in response to morphine administration.

Simi-

larly, an acute dose of haloperidol, which increased striatal dopamine turnover in naive and chronically haloperidol
treated rats was only marginally effective in morphine dependent rats (Lal, et al., 1976).
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It has been previously demonstrated that supersensibility develops to the aggression-eliciting effects of apomorphine in rats withdrawn from chronic morphine or haloperidol (Puri and Lal, 1973; Gianutsos et al., 1974; Lal et al.,
1975).

After chronic morphine administration supersensitiv-

ity also develops to apomorphine's effect on striatal
dopamine turnover (Lal, et al., 1976).

Doses of apomorphine

which were previously ineffective in naive rats cause a
marked inhibition of striatal dopamine turnover in rats withdrawn from chronic morphine or haloperidol.
(2)

Adenylate Cyclase Activity
The relationship between opiates and the

cyclic AMP-adenylate cyclase system has been examined in a
number of ways.

Peripheral administration of cyclic AMP an-

tagonized morphine analgesia and increased withdrawal signs
in morphine-tolerant animals (Ho et al., 1972; 1973).

The

injection of cyclic AMP into the lateral ventricles of rats
also increased withdrawal signs in tolerant animals (Collier
and Francis, 1975).
An acute injection of morphine (60 mg/kg) has been
found to produce significant increases in cyclic AMP levels
in midbrain, cerebellum, striatum and cortex 15 to 30 minutes
after the injection (Clouet and Iwatsubo, 1976).

While in

the hypothalamus, medulla and cerebellum, the levels of
cyclic AMP were significantly lower than control values two
hours after the injection of morphine (Clouet, et al., 1975).
In morphine tolerant rats sacrificed two hours after the last
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twice-daily injections for 10 days, the levels of cyclic AMP
were at control levels or higher, indicating that tolerance
to the decreased cyclic AMP had developed (Clouet et al.,
1975).
Adenylat e cyclase activity was increased in midbrain
and striatum one hour after the injection of 60 mg/kg morphine or 15 mg/kg levorphonal, but not after 15 mg/kg dextrorphan (Clouet and Iwatsubo, 1976).

The enzyme activity was,

however, decreased by narcotic agonists in the cerebellum.
In tolerant animals, cerebellar adenylate cyclase activity increased by a morphine challenge, as it was in midbrain and
cortex, again indicating a tolerance in cerebellar cyclase
(Clouet et al., 1975).
Dopamine-sensitive adenylate cyclase activity in
shocked preparations of striatal synaptosomes was found to
increase after acute morphine treatment above control dopamine-stimulation (Clouet and Iwatsubo, 1976).

Although the

basal cyclase activity was found to increase above control
levels from 15 to 60 minutes after morphine injection, the
absolute stimulation by 100

JIM

dopamine was significantly

higher at 30 minutes to 2 hours after the injection of the
opiate than stimulation by dopamine in preparations from
untreated rats.

The percent stimulation by dopamine was

similar at each time point after acute morphine treatment
(Iwatsubo and Clouet, 1975).

The basal adenylate cyclase

activity in striatal nerve endings was unchanged after rats
were made tolerant by morphine pellet implantation. However,
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when rats were made dependent by increasing doses of morphine
a significant increase in the basal levels of adenylate cyclase was observed.

The increase was seen from 1 to 72 hours

after the last injection of 100rphine and was therefore not
related to the acute effects of morphine.

The elevated levels

of adenylate cyclase activity could not be further stimulated
by in vitro addition of dopamine {Lal et al., 1976).
3.

Endocrinological Similarities
a.

Adrenocorticotropin Hormone
Current evidence indicates that adrenocortico-

tropin {ACTH) is under dual hypothalamic control {Fortier,
1966) and neurochemical findings have in addition led to the
proposal of adrenergic-inhibitory and cholinergic-stimulatory
regulation of ACTH secretion {Ganong, 1972; de Wied and de Jong,
1974, Marks et al., 1970).

In considering the effects of nar-

cotics on pituitary function, it must be determined if morphine interferes with the basal secretion of ACTH, the release
of ACTH in response to stress and the circadian rhythm of
ACTH secretion.
Acute morphine administration in rats stimulates ACTH
secretion {Briggs and Munson, 1955; George and Way, 1955;
Nikidijevic and Maickel, 1967).

Using the depletion of adren-

al ascorbic acid as a measure of ACTH release it has been reported that a single injection of morphine enhances the
secretion of ACTH in the unanesthetized rat {George and Way,
1955; Nasmyth, 1954; Van Peenen and Way, 1957; Briggs and
Munson, 1955; Nikodijevic and Maichel, 1967; Lotti et al.,
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1969).

Similar findings have been reported following acute

administration of (+) and (-) methadone (George and Way, 1955).
Preadministration of nalorphine in small doses inhibits the
adrenal ascorbic acid depletion effect of both morphine
(George and Way, 1955; Burdette et al., 1961) and the isomers
of methadone (George and Way, 1955).

The effects of morphine

on ACTH are also completely blocked by naloxone (Kakka and
George, 1974).

These results suggest that the ACTH releasing

effects of these drugs are mediated via specific neural pathways and/or narcotic receptors.

This ascorbic acid depleting

effect of morphine and methadone is dependent upon an intact
pituitary-adrenal axis since it is abolished by hypophysectomy (George and Way, 1955).
A more direct measure of pituitary-adrenal activity is
reflected by changes in the plasma level of corticosteroids.
The effect of acute morphine administration on adrenal cortical hormone secretion appears to be species dependent (George
and Lomax, 1972).

Several reports have clearly shown that a

single injection of morphine is capable of elevating plasma
corticosterone levels in conscious rats (Nikodijevic and
Maickel, 1967; Lotti et al., 1969; Oliver and Troop, 1963;
Shusher and Browning, 1961) and plasma 17-hydroxycorticosterone levels in dogs (Suzuki et al., 1959).

However, this has

not been confirmed in studies on the guinea pig (Sobel, et
al., 1958) and man (Eisenman et al., 1958).
Although the mechanism by which morphine exerts these
effects is not clear, it is however evident that it is
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mediated by the central nervous system (George and Lomax,
1972; Kokka and George, 1974; Zimmermann and Critchlow, 1973).
The studies of George and Way (1959) in rats with hypothalamic
lesions that were challenged with morphine and those of Lotti
et al.,

(1969) in which rats were injected intrahypothalami-

cally with micro-quantities of morphine, have indicated that
the integrity of the hypothalamic-pituitary axis is essential
for these actions of morphine.

It was found that hypothalam-

ic lesions, primarily in the anterior medial eminence blocked
the ascorbic acid depleting effect of morphine.

Conversely,

injections of microgram amounts of morphine into this hypothalamic region reduced adrenal ascorbic acid while elevating
plasma corticosterone levels.

Thus most of the available

evidence indicates that morphine activation of ACTH secretion
is mediated via a direct action on the rostral region of the
hypothalamus and medial eminence (George and Way, 1959; Lotti
et al., 1969; Zimmermann and Critchlow, 1973), although extrahypothalamic sites and peripheral mechanisms can not be excluded (Kokka and George, 1974).
The chronic administration of morphine to rats produces a marked adrenal cortical hypertrophy.

This observa-

tion was first made in 1926 by McKay and McKay and has been
confirmed by others

(George and Way, 1959; Tanabe and Cafruny,

1958; Sloan et al., 1963; Sloan and Eisemann, 1968). Investigations in which different parameters of pituitary-adrenal
activity were studied seem to indicate an opposite effect,
for example chronic administration of morphine depresses the

59

basal level of adrenal cortical secretion. The injection of
morphine into guinea pigs for 12 days was found to reduce
the basal level of urinary 17-hydroxysteroids (Sobel et al.,
1958).
man.

Similar findings have been observed in the rat and in
Paroli and Melchiorri (1961) injected rats for periods

ranging between 10 to 40 days and 40 to 100 days and noted a
decrease in the urinary levels of hydroxysteroids.
study on human addicts Eisenmann et al.

In a

(1961) found that two-

to-four month cycles of morphine addiction reduced both plasma
and urinary 17-hydroxycorticosteroid levels.

They showed

that this reduction in the basal secretory rate of adrenal
cortical hor:rrones was due chiefly to a decrease in the proauction of 17-hydroxycorticosteroid.
Chronic administration of morphine may also depress
the pituitary adrenal response to a variety of stresses. In
rats treated with morphine for a five-day period, the response to several stresses was blocked (Munson and Briggs,
1955).

In other investigations on rats injected with mor-

phine for 25 days (Paroli and Melchiorri, 1961) and guinea
pigs injected for 12 days

(Sobel et al., 1958) it was re-

ported that the increase in urinary hydroxysteroids in response to cold stress - was inhibited.

On the basis of these

findings it would appear that chronic morphine administration produces a depression in the basal secretion of adrenal
cortical hormones and prevents pituitary-adrenal activation
in response to numerous stresses.

However, in a study with

methadone-treated heroin addicts, Cushman et al.

(1970)
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found no differences in basal plasma 17-hydroxycorticosteroid levels of addicts from normal control valves, also chronic
methadone treatment did not interfere with the metyrapone
test, which produces an increase in urinary 17-ketogenic steroids,or _to the stress of insulin hypoglycemia, as reflected
by elevated plasma 17-hydroxycorticosteroid (17-0HCS) levels.
The normal diurnal pattern of 17-0HCS also may be altered by the chronic administration of morphine and methadone.
Eisenmann et al.

(1961) found that morphine interfered with

the early morning rise of plasma 17-0HCS; they also noted the
presence of a mid-day increase of plasma 17-0HCS during the
period of morphine administration.
et al.

The results of Cushman

(1970) in general, corroborate these findings.

They

were able to show that chronic methadone treatment in a group
of 16 heroin add i cts altered the normal diurnal variations of
plasma 17-0HCS in 10 of the 16 subjects.
In both the rat and man, abrupt withdrawal of morphine
res u lted in increased adrenal cortical activity (George and
Lomax, 1972).

Rats given morphine chronically and then

abruptly withdrawn from the d rug or administered nalorphine
show an increase in levels of urinary 17-0HCS, 17-ketosteroids
and aldosterone (Paroli and Melchiorri, 1961).

In man, also,

the abrupt withdrawal of morphine produces a marked increase
in plasma and urinary 17-0HCS and an elevation in urinary 17ketosteroids (Eisenmann et al., 19 61) .

The maximal rlse in

adrenal cortical levels correlates well with the peak physiclogical effects of the abstinence syndrome, approximately 48
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hours after withdrawal.
Although there are numerous reports regarding the effeet of chlorpromazine on pituitary adrenal function, it is
not clear whether chlorpromazine stimulates or inhibits ACTH
secretion.

The discrepancies could arise from a number of

factors, the dose of chlorpromazine, the time chlorpromazine
was administered prior to stress challenge, the cor e temperature of the stressed animal and the parameter of pituitary
adrenal activation employed.
In general, numerous studies in rats have indicated
that small doses of chlorpromazine do not alter adrenal ascorbic levels to an appreciable degree, larger doses deplete
ascorbic acid {de Wied, 1967; George and Lomax, 1972).

Both

small and large doses of chlorpromazine have been reported
to have no effect; a partial blocking effect, or complete
blocking effect on the ascorbic acid depletion response to
several types of stress {de Wied, 1967; George and Lomax,
1972).

Marks et al.

{1970) have shown that a single injec-

tion of chlorpromazine {25 mg/kg) was capable of lowering
hypothalamic corticotropin-releasing factor, while simultaneously elevating plasma corticosterone levels.

When the

corticotropin-releasing factor content of the ventral hypothalamus returned to control levels it was found to be closely
related to the return to normal adrenal corticosterone levels.
Marks et al.

{1970) interpret the blockade of stresses fol-

lowing chlorpromazine-administration as being due to the
possibility that corticotropin-releasing factor secretion has
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become maximal, which is the result of removal of inhibitory
neural influences by chlorpromazine.
The results obtained from other species are more consistent.

Using plasma 17-0HCS as an index of pituitary

adrenal activity, it has been shown that chlorpromazine increases ACTH secretions in the guinea pig (Sasaki, 1963) dog
(Egdahl and Richards, 1956; Betz and Ganong, 1963) and monkey
(Harwood and Maon, 1957).

This effect of chlorpromazine is

abolished by hypophysectomy (Egdahl and Richards, 1956),
thereby placing the site of action at the pituitary or hypothalamus.
Chronic administration of chlorpromazine like morphine
produces adrenal cortical hypertrophy, but, unlike morphine,
does not consistently prevent adrenal activation in response
to stress (de Wied, 1967).

In patients treated with chlor-

promazine, the ACTH response to the stresses of insulin
(Christy et al., 1957) and typhoid vaccine (Fotherby et al.,
1959) is inhibited.
b.

Antidiuretic Hormone
It is well established that morphine and its

surrogates produce an antidiuretic effect in certain animals
(Fujimoto, 1971; Hayward, 1974).

The bulk of evidence

(Fujimoto, 1971; Hayward, 1974) favors the concept first proposed by de Bodo (1944) that the antidiuretic effect of
morphine in the dog is due to release of antidiuretic hormone.
However, many of the studies on the antidiuretic effect of
morphine are contradictory, depending on the species and
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dosage employed, route of administration, presence or absence
of anesthetic agents, and the development of tolerance.

Stu-

dies showing convincing antidiuretic hormone release by morphine were performed in the dog (Fujimoto, 1971; de Bodo,
1944; Duke et al. 1951; Handley and Keller, 1950), rat (George
and Way, 1959) and monkey (Hayward, 1974) but studies in man
show either a primary change in renal hemodynamics

(Papper

and Papper, 1964; Habif et al., 1951) or a diuretic effect
(Fujimoto, 1971).
Neuroleptics have been found to induce antidiuretic as
well as diuretic effects, and their action on antidiuretic
hormone release are not clear (Gaunt et al., 1963; de Wied,
1967).
A dose response relationship has been reported for the
antidiuretic action of chlorpromazine (Meier et al., 1955;
Supek et al., 1960).

In addition, in rats anesthetized with

alcohol a very low dose of chlorpromazine elicited a marked
antidiuresis while in rats with diabetes insipidus the antidiuretic effect of chlorpromazine was no longer demonstrable.
This observation suggests that the antidiuretic effect of
chlorpromazine is due to increased release of antidiuretic
hormone (de Wied, 1967).

High doses of chlorpromazine given

over a several-day period may depress synthesis of antidi uretic hormone (de Wied, 1967) and in lower dose levels may
inhibit antidiuretic hormone release in response to hypertonic salt loading or to painful stimuli (Shibusawa et al.,
1955; de Wied and Jinks, 1958).
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c.

Gonadotropins
Morphine administration has been shown to ef-

fect the secretion of gonadotropins (George and Lomax, 1972;
Barraclough and Sawyer, 1955).

One of the earlier sugges-

tions that morphine can alter pituitary gonadotropic hormone
secretion was from a survey in which it was found that human
female addicts exhibited decreased libido, amenor.theaand
sterility during a period of morphine addiction.

In many of

these cases, even though the menstrual cycles returned to
normal after withdrawal from the drug, sterility persisted
(Menninger-Lerchenthal, 1934).

Barraclough and Sawyer (1955)

found that administration of morphine between 12 and 2 P.M.
on the day of proestrus in rats prevents ovulation.

Chroni-

cally injected morphine daily between 12 and 2 P.M. inhibits
ovulation for a considerable period of time.

Tolerance to

the drug results in the recurrence of ovulation, although
cycles remain irregular.
near the medial eminence.

The site of the morphine effect is
Electrical stimulation in the

medial eminence, but not in the posterior tuberal region,
overcomes the morphine blockade of ovulation (Sawyer, 1963).
Addicts have irregular menstrual cycles and decreased gonadotropin secretion as reflected by a diminished urinay excretion of 17-ketosteroids, while the response to exogenous
gonadotropins is enhanced (Eisenmann et al., 1958; Hollister,
1973; Stoffer, 1968). Chronic administration of morphine to
male rats has been shown to produce atrophic changes in
their seminal vesicles and prostates (George and Lomax, 1972).
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Although these data are indicative of a luteinizing hormone
suppressing effect of morphine, there is also some evidence
in favor of a follicle-stimulating hormone inhibiting action
of morphine. Rennels (1961 ) found that two weeks of morphine
administration produced changes in pituitary cytology and
gonadotropin content which were indicative of folliclestimulation hormone suppression and without effect on luteinizing hormone secretion.

In summary, it is apparent that

morphine administration, either acute or chronic, inh i bits
gonadotropin secretion.

Although there is evidence for a

morphine inhibitory effect on both follicle-stimulating hormone and luteinizing hormone secretion, most of the evidence
points to an interference with luteinizing hormone release
{George, 1971; George and Lomax, 1972; de Wied et al., 1974).
The endocrine system most uniformly affected by the

-

phenot.~iazines

is the pituitary-gonad axis.

Numerous investi-

gations in a variety of species have shown that either acute
or chronic administration of phenothiazines inhibits secretion of pituitary follicle-stimulating hormone and luteinizing hormone.

Phenothiazines have produced some of the follow-

ing effects which are indirect indices of depression of
follicle-stimulating hormone and luteinizing hormone secretion:
failure of ovulation, delayed sexual maturation, reduction in
weight of ovaries,

uteri and vaginae, reduction in size of

sex organs in the male, and inhibition of compensatory ovarian hypertrophy {de Wied, 1967).
While most of the evidence points to an inhibitory
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effect of chlorpromazine on hypothalamic pituitary function,
there are data that suggest the possibility of a blocking action of chlorpromazine at the target gland.

In large doses

chlorpromazine has been found to block the action of gonadotropins on target glands in both sexes (Meidinger, 1954;
Zarrow and Brown-Grant, 1964).

However, data contrary to

these findings raise doubts regarding the target gland as
the site of chlorpromazine action (de Wied, 1967; de Wied and
de Jong, 1974).
The results reported from animal studies have also been
observed in the human female. Chlorpromazine administered one
to three days prior to ovulation delays menstruation for a
period of 8 to 16 days (Wheklaw, 1956). Also, many reports
show that chlorpromazine treatment may produce menstrual irregularities and amenonhea (de Wied, 1967).

Butyrophenone

type neuroleptics have many of the same endocrine effects as
the phenothiazines (Byck, 1975).
d.

Growth Hormone
Morphine and methadone have been found to dose

dependently elevate plasma concentrations of growth hormone
(Howard and Martin, 1971; Wakaboyaski et al., 1971; Kokka
et al., 1972; 1973; Kokka and George, 1974).

Nalorphine,

which has many of the agonist properties of morphine, also
produced increases in plasma concentrations of growth hormone
(Kokka and George, 1974).

Naloxone, a pure antagonist, was

without effect on growth hormone.

The morphine increase in

plasma growth hormone was not blocked by naloxone (Kokka and
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George, 1974).

Chronic morphine administration does not re-

sult in tolerance to its effects on growth hormone (Kokka et
al., 1973; Kokka and George, 1974).

Bilateral electrolytic

lesions of the ventromedial nucleus did not affect morphineinduced stimulation of growth hormone secretion.

These re-

sults suggest that morphine stimulation of growth hormone
secretion may be due to a direct effect on the anterior pituitary, but i t is also possible that morphine acts at the level
of the median eminence to inhibit release of growth hormoneinhibiting factor

(Kokka and George, 1974).

The secretion of growth hormone is under the control
of sornatotropin release-inhibiting hormone (Brazeau et al.,
1973) and growth hormone releasing hormone (Deuben and
Meites, 1964).

The influence of dopaminergic neurons on

growth hormone release is unclear.

Pimozide, a dopamine re-

ceptor blocker, elevates plasma growth hormone in rats

(Mue.lih.ex et .al.,1973).

While plasma growth hormone in rats

is dramatically reduced by haloperidol, with a dose of 0.3
mg/kg causing levels to fall below 20 percent of control
values (Muller et al., 1976).

Haloperidol also blocked the

apomorphine-induced stimulatio n of growth hormone secretion
(Mueller et al., 1976).

Chlorprornazine has also been found

to inhibit secretion of growth hormone (Byck, 1975) and to
block the L-DOPA-induced stimulation of growth hormone in
man (Mims et al., 1975).

Chronic chlorprornazine administra-

tion has been reported to have no effect on body growth in
rats (Meidinger, 1954) or to inhibit growth in mice (Cranston
and Segal, 1958).
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e.

Prolactin
Prolactin is a hormone produced by the anterior

lobe of the pituitary gland.

It is capable of initiating

and sustaining lactation, but only when other essential hormones such as estrogen, progesterone and oxytocin are present.

The effect of morphine and related compounds on pro-

lactin release has not been studied extensively.

Several

years ago, Meites (1966) reported that acute administration
of morphine stimulates lactation in the rat, indicating an
increase in the discharge of prolactin.

Recently, increased

circulating levels of prolactin have been observed in rats
following systemic (Zimmermann et al., 1974) or intraventricular (Mccann et al., 1974) administration of morphine.
The effects of neuroleptics on prolactin levels have
been more extensively studied.

The administration of tran-

quilizers to some patients has long been known to cause
breast enlargement and galactorrhea (MacLeod, 1976). Phenothiazine derivatives, especially perphenazine, have long
been known to induce mammary development and initiate milk
secretion in many species.

Injection of perphenazine causes

a prompt increase in serum prolactin levels (Ben-David et
al., 1970); Lu et al., 1970; MacLeod and Lehmeyer, 1974)
and increases synthesis of the hor mone (MacLeod and Lehmeyer,
1972). Dickerman et al.

(1972) showed that as little as

10 ug haloperidol per 100 grams body weight increased serum
prolactin levels.

Th e inhibition produced by dopamine of

the in vitro secretion of both 3 H-prolactin and of radio-
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imrnunoassayable prolactin was reversed by coincubation with
5 x 10

-9 M haloperidol {MacLeod, 1976).

The neuroleptic drug

pimozide has also been found to be a potent stimulator of
prolactin secretion.

Injecting the drug into rats signifi-

cantly increases the circulating level of prolactin and the
in vitro capacity of the pituitary to synthesize the labeled
hormone {MacLeod, 1976).

Pimozide also rendered the rat

pituitary gland refractory to the usual inhibitory in vitro
action of dopamine {MacLeod and Lehmeyer, 1973; 1974) and
thus has a pharmacological action similar to perphenazine
and haloperidol.
Chronic morphine treatment has been found to decrease
the release of prolactin {de Weid et al., 1974).

However,

prolactin levels in methadone-treated males have been found
to be within normal limits {Cushman and Kosek, 1974).

With-

drawal from chronic treatment with morphine has been found
to result in lower circulating levels of serum prolactin in
male rats {Lal et al., 1977).
Rats receiving chronic daily injections of perphenazine demonstrate an increase in prolactin synthesis, and in
male rats the drug caused a fivefold increase in in vitro
prolactin secretion {MacLeod, 1976).

The pituitary glands

from these perphenaz·ine-treated rats when incubated with
dopamine, failed to exhibit the usual prolactin inhibiting
action of dopamine {MacLeod, 1976).

An implant of pimozide

in the pituitary gland or in the median eminence-arcuate
region produces a gradual increase in serum prolactin {Ojeda
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et al., 1974).

Withdrawal from chronic haloperidol treatment

has been found to result in lower circulating levels of serum
prolactin in male rats

(Lal et al., 1977).

These results

suggest hyperactivity of the tubero-infundibular dopamine system (Lal et al., 1977).

The tubero-infundibular dopamine

neurons are responsible for a tonic inhibitory effect on the
release of prolactin (de Wied and de Jong, 1974; Kamberi,
1973; Collu et al., 1973).
f.

Thyroid Hormone
Nearly all of the studies regarding the effects

of narcotic analgesics on pituitary-thyroid function indicate
that these agents inhibit basal thyroid secretion (George
and Lomax, 1972).

Single intravenous injections of morphine,

meperidine, levorphanal, dextrorphan and dihydromorphinone,
have been reported to stimulate thyrotropin (TSH) release as
measured by the release of thyroidal 131 1 (George and Lomax,
1972). The chronic injection of all of these compounds for a
period of five-day inhibited thyroid activity (Redding et
al., 1966).

Codeine administered to rats for 14 days has

been found to lower basal thyroid function; however, codeine
did not prevent hypersecretion of TSH since it did not block
the thyroid hypertrophy induced by methylthiouracil
(Schreiber, 1968).
Chronic morphine administration for three weeks decreased pituitary TSH content (Hohlweg et al., 1961}.

In-

jection of morphine for periods of three or five days inhibits release of

131

r-labeled thyroid hormone (George and
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Lomax, 1965), depresses 131 r uptake by the thyroid and reduces
thyroid and pituitary weights

(Samel, 1958).

These data show

that morphine may have a dual action on the pituitary-thyroid
axis

(George and Lomax, 1972).

A single injection of mor-

phine accelerates the release of 131 r-labeled thyroid hormone

in mice, whereas administration of morphine for a period of
three days or longer inhibits several parameters of thyroid
activity in rats

(George and Lomax, 1972).

Although the mechanism through which this inhibition
occurs is not known, there are several lines of evidence
which implicate hypothalamo-hypophysial involvement.
thalamic control of TSH is well established.

Hypo-

Anterior hypo-

thalamic lesions block the goitrogenic effects of propylthiouracil (Greer, 1952) whereas electrical stimulation of
this area enhances TSH secretion (Harris and Woods, 1958).
On the basis of these findings, Lomax and George

(1966) stu-

died the effect of morphine on thyroid activity in rats with
hypothalamic lesions.

They found that lesions in the caudal

region of the hypothalamus completely blocked the morphineinduced thyroidal inhibition, but animals with lesions in
the anterior hypothalamus displayed normal
lease rates.

131

r thyroidal re-

Lomax and George (1966) suggest that morphine

might be activating an inhibitory hypothalamic area

rather

than depressing a facilitatory one for the secretion of TSH.
In a subsequent study Lomax et al.

(1970) found that intra-

hypothalamic administration of microquantities of morphine
(5 pg) produced inhibition of thyroid activity when the drug
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was injected into both rostal and caudal regions of the hypothalamus.

The extent of inhibition was found to vary with

the injection site.

Injections of morphine into the caudal

hypothalamus inhibited release of

131 1-labeled thyroid hor-

mone throughout the period of drug administration, while
injection of morphine into the rostal site produced a transient inhibition, suggesting the development of tolerance in
this area.

Since there is some evidence that electrical

stimulation of the caudal hypothalamus may inhibit TSH secretion (Vertes et al., 1965) and since injection of morphine
into the caudal hypothalamus produces hyperactivity and hypertherrnia (Lotti et al., 1965), Lomax et al.

(1970) suggested

that morphine was producing its thyroid inhibiting effect
primarily via stimulation of inhibitory neurons in the
caudal hypothalamus.
Conclusions drawn from experiments on the effect of
neuroleptics on thyroid function vary considerably.

This is

caused by the various measures used to determine thyroid activity, the different dosages and the duration of the treatment employed, and differences i n experimental circumstances,
especially with regard to environmental temperature.

131

Using

1-uptake by the thyroid as a measure of pituitary-thyroid

activity, several workers observed a decrease in uptake after
a relatively high dose of chlorpromazine (Arvay et al., 1960;
Wiseman, 1962; Ksycki and Lockett, 1965; de Wied, 1967).
Doses of 10 mg of chlorpromazine per kg and lower generally
do not depress

131 1-uptake by the thyroid (Wiseman, 1962;
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Wright, 1958), but Milcou et al.,

(1955) found a depression

with about 6 mg/kg.
131

Inhibitory effects on

I-uptake may be the result

of a central effect or of a direct action of chlorpromazine
either on iodine trapping or on peripheral mechanisms.

Di-

rect effects of chlorpromazine on synthesis of thyroid hormone in a dose of about 10 mg/kg have been observed by
Ksychki and Lockett (1965). They found that incubation of
thyroids from mice treated with chlorpromazine exhibited reduced organic binding of 131 I.

Evidence for a direct action

of chlorpromazine on the thyroid has been also derived from
studies by Mayer et al.

(1956).

with thyroid slices depressed

Incubation of chlorpromazine

131

I trapping by the gland,

while later stages of the iodine cycle proceeded abnormally
only if high doses were used.
The rate of release of

131

I by the thyroid has for

some time been regarded as the most reliable indirect parameter of pituitary-thyroid activity (Brown-Grant et al., 1954;
de Wied, 1967).

It has been employed by a few investigators

for the study of chlorpromazine on thyroid function (Foldes
et al., 1959; George and Lomax, 1965; Milcou et al., 1955;
Wright, 1958). George and Lomax (1965) found that 5 mg/kg
of chlorpromazine decreased

131

I-release by the thyroid in

intact as well as adrenalectomized rats. Since TSH accelerated

131

I-release in chlorpromazinet:reated animals, it seemed

likely that thyroid activity was not directly blocked by the
drug (de Wied, 1967).

74

The effects of chronic treatment with chlorpromazine
on thyroid function have been studied with a variety of func131
tional and morphological parameters. A reduction in
Iuptake by the thyroid in rats chronically treated with chlorpromazine (2 to 100 mg/kg/day) has been demonstrated (Arvay
et al., 1960; Reiss, 1958; Wiseman, 1962; Wright, 1958). The
release of 131 I from the thyroid is similarly depressed by
chronic treatment (Foldes et al., 1959; Samuel, 1958; Wright,
1958). These results suggest that thyroid function is blocked
in animals on long-term basis with chlorpromazine.

However,

other studies (de Wied, 1967; Arvay et al., 1960; von Brauchitsch, 1961) have shown a biphasic effect on

131

I-uptake by

the thyroid after long-term administration of high doses of
chlorpromazine.

Initially, during the first two to three
131
.
.
h ave f oun d an in
. h'b'
.
i ition
of
Id ays, t h ese investigators
uptake which is then followed 9 to 10 days later by an in-

creased uptake of

131

I.

Long-term administration of chlor-

promazine also has been noted to produce goiter in the rat
(Sulman, 1959), although chlorpromazine paradoxically partly
inhibits the goitrogenic effect of thiouracil derivatives
(Aleshin and Us, 1960; Meidinger, 1954).

The effects of

chronic chlorpromazine administration in man are difficult
to interpret since most patients receiving chlorpromazine
have psychiatric disorders.

Most of the studies in man have

failed to show changes in thyroid activity (de Wied, 1967),
although it has been reported that chlorpromazine may increase thyroidal 131 I-uptake without interfering with other
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parameters of thyroid functions

(Blumberg and Kelin, 1969);

George and Lomax, 1972). Although the mechanism by which chlorpromazine interferes with the action of TSH on thyroid tissue
has not clearly been established, there is some evidence
which favors an interference at the adenyl cyclase - cyclic
AMP level (Yamashita et al., 1970; Wolff and Jones, 1970) as
well as the lysosomal membrane level (Onaya, 1969; Williams
and Wolff, 1971).
In summary, there is evidence that acute administration
of the phenothiazines may inhibit both the uptake and release
of thyroid

131

I, indicative of reduced TSH secretion, but that

chronic administration reverses these effects.

In vitro ex-

periments suggest that chloropromazine interferes with thyroid function by interfering with the action of TSH on the
thyroid.

F.

Methods for the Production of Physical Dependence
A large number of methods have been devised for induc-

ing narcotic tolerance and dependence in laboratory animals.
These different techniques may be distinguished by the route,
frequency and method of drug delivery to the animal.

The ob-

jectives of these experimental maneuvers are to minimize
acute toxicity while effecting a sufficiently high narcotic
intake so that a high degree of tolerance and dependence will
rapidly develop.

Some of the more extensively and thoroughly

investigated models for producing narcotic dependence are
daily parenteral injections, oral intake via water or food,
implantation of pellets and infusion.
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1.

Parenteral Injections
Laboratory animals have traditionally been made de-

pendent on morphine through intraperitoneal or subcutaneous
injections of the drug on a regular basis for relatively long
periods of time {Himmelsbach et al., 1935; Martin et al.,
1963; Akera and Brody, 1968; Buckett, 1964; Hynes et al.,
1976).

The procedure of Martin et al.

(1963) is a typical

example of the intraperitoneal method, which is the most common of the injection regimens for addicting rats.

The initial

dose of morphine was 5 mg/kg administered intraperitoneally
twice daily at 8 A.M. and 3 P.M.

The dose was increased bi-

weekly until the rats were receiving 320 mg/kg/day by the
thirty-fifth day of addiction.

The rats were stabilized at

this dose level for a week and the morphine was withdrawn
abruptly.

Other investigators have employed one daily dose

of narcotic {Wikler et al., 1963) while others have employed
three {Akera and Brody, 1968 ; Hynes et al., 1976) and even
four daily narcotic injections {Puri and Lal, 1973).

Ava-

riety of terminal morphine doses have also been employed.
Terminal morphine doses have ranged from 30 mg/kg/day {Akera
and Brody, 1968) to over 400 mg/kg/day {Buckett, 1964; Puri
and Lal, 1973; Hynes et al., 1976).

Although many investi-

gators administer the narcotic by the intraperitoneal route
{Martin et al., 1963; Buckett et al., 1964; Puri and Lal,
1973; Hynes et al., 1976) others have used subcutaneous injections {Akera and Brody, 1968).
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Mice have also been rendered tolerant to and physically
dependent on morphine by daily subcutaneous injections of increasing doses of morphine {Loh et al., 1969; Marshall and
Grahame-Smith, 1971).

Morphine has been injected three times

a day in these procedures.

Loh et al.

(1969) used a starting

dose of 10 mg/kg which was gradually increased over a threeweek period until 200 mg/kg was given every 8 hours, while a
maximum of only four days of morphine administration was employed by Marshall and Grahame-Smith (1971).
Both abrupt withdrawal and precipitated withdrawal have
been employed after the chronic injection of morphine.

Dur-

ing abrupt withdrawal loss of body weight, body shakes, hypothermia, piloerection, ptosis, loose stools and aggression
have been noted {for review see Granutsos et al., 1975). After
the precipitation of withdrawal by a narcotic antagonist,
loss of body weight, jumping, diarrhea, piloerection and body
shakes have been observed {Marshall and Grahame-Smith, 1971;
Blasig et al., 1976).
The administration of narcotics by daily injection is
a reliable method for the induction of physical dependence
that is widely employed. There are, however, several drawbacks to this technique.

For example, it requires that the

researcher spend part of his time injecting animals on a
regular basis.

There is also a possibility of producing skin

inflammation, injury and infection.

Large amounts of nar-

cotics are needed to establish dependence according to this
method.

78

2.

Oral Consumption
The oral route of narcotic administration is another

method which has been employed by several investigators to induce dependence in laboratory rats (Risner and Khavari, 1973;
Stolerman and Kumar, 1970; Shuster et al., 1963; Wikler et
al., 1963).

Although the oral ingestion method is simple and

economical, there are some difficulties associated with it.
The amount of morphine solution ingested by rats is apparently
limited by at least two factors.

First, the highly bitter

taste of the opium alkaloid appears to be aversive to animals
~

even at low concentrations. Secondly, the animals consume
relatively constant quantities of water to satisfy bodily
fluid requirements (Khavari and Risner, 1973).
One method used to overcome these problems has been to
force animals to drink narcotic solutions in order to relieve
their thirst.

Wikler et al.,

(1960) found that normal rats

deprived of water for twenty-two hours drank an aqueous solution of etonitazene methane sulfonate avidly.

Within seven

minutes after starting to drink this potent narcotic the rats
exhibited exophthalmos,

tail rigidity and periods of stupor

and/or hyperactivity (Wikler et al., 1960).

After twenty-

four hours of abstinence similarly water-deprived addicted
rats (maintained on a single subcutaneous dose of morphine,
200 mg/kg/daily) also drank a solution of etonitazene avidly.
These rats showed not only morphine-like effects but also the
disappearance of withdrawal body shakes

(Wikler et al., 1960;

Wikler et al., 1963). Further investigation revealed that
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rats drink an aqueous solution of etonitazene in substantial
quantities even without prior water-deprivation (Wikler et
al., 1963). When only the etonitazene solution is available
for drinking during abstinence, morphine-addicted rats consume significantly greater quantities of the etonitazene solution than they do of water during the same period and at
the end of etonitazene consumption period body shakes are reduced (Wikler et al., 1963).

Stolerman and Kuman (1970) also

forced rats to drink morphine solutions in order to relieve
their thirst.

They found that these rats overcame their aver-

sion for morphine solutions and eventually preferred them to
water.
Narcotics have been administered in milk or sucrose
solutions in order to reduce the adversive taste of the opiates.
Mice have been reported to become tolerant and dependent by
drinking large quantities of dilute evaporated milk containing dihydromorphinone (Shuster et al., 1963).

When these

mice were withdrawn they lost body weight indicating that
physical dependence had been established. The addicted mice
showed no clear preference for milk containing the narcotic
when allowed a choice between plain milk and dihydromorphinone milk

(Shuster et al., 1963).

A procedure for a highly

effective and reliable method for oral morphine administration has been developed by Khavari and Risner (1972; 1973).
Specifically, they found that rats would ingest large quantities of morphine when the drug was presented in a sucrose
medium and that they would prefer sucrose morphine over the
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sucrose vehicle in subsequent two-bottle choice test (Khavari
and Risner, 1972).

The morphine-sucrose solution was effec-

tive in producing morphine dependence in rats. This conclusion
was confirmed by the presence of withdrawal signs such as
body weight loss, anorexia and adipsia when the morphine was
withheld or nalorphine was administered (Khavari and Risner,
1973).
The possibility of adding morphine directly to the animals food as a method for inducing physical dependence has
not been extensively investigated.

This method was used by

Sollman (1924) in a limited way but he reported that dependence did not develop as measured by the effects of subsequent
removal of morphine from the food.

Sollman's experiment

represented the only attempt to induce dependence using morphine-adulterated food until Madinaveitia's (1969) examination of this method.

He also observed that in rats which for

several weeks had morphine added to their food in concentrations up to 1 mg/g there was no significant changes seen upon
withdrawal.

More recently Khavari and Risner (1973) investi-

gated the ingestion of morphine adulterated food in rats.
They found that those animals maintained on concentrations
of 1 mg/g morphine in the food showed a preference for morphine-adulterated

food over regular food in a choice test.

Those rats given concentrations of 3 or 4 mg/g morphine
showed severe withdrawal signs when they failed to maintain
their morphine intake in the food choice test.

These signs

varied in intensity as a direct function of the animals'
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prior morphine intake and indicated they were morphine dependent (Khavari and Risner, 1973).

Therefore, it seems that

either morphine dependence or forced treatment seems to be
essential for the rat to show preference for morphinized food.
3.

Pellet Implantation
In recent years, a morphine pellet implantation pro-

cedure has been employed to produce tolerance and physical
dependence in the mouse, rat and guinea pig.

The implanta-

tion technique was originated by Maggiolo and Huidobro (1961)
who made a pellet by compressing 75 mg of morphine base under
high pressure. Such a pellet proved cumbersome to make and
its absorption is not rapid enough to produce physical dependence of a magnitude that can be measured by abrupt withdrawal,
although striking abstinence signs could be precipitated by
injection of nalorphine (Maggiolo and Huidobro, 1961).

Gibson

and Tingstad (1970) made improvements in this pellet and this
new formulation has been widely used for the quantitative assessment of tolerance and physical dependence (Way et al.,
1969; Ho et al., 1972; Wei et al., 1973; Wei, 1973).

Theim-

plantation procedure has gained considerable popularity because of its ease and suitability for rapidly inducing tolerance and physical dependence.

The pellets are implanted

under light anesthesia subcutaneously in the back or in the
lower abdominal wall (Wei and Way, 1975). Between twenty-five
and fifty percent of the morphine in the pellet is absorbed
in the first two days after implantation, after which the
rate of absorption of morphine plateaus (Way et al., 1969;
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Blasig et al., 1973; Goldstein and Schultz, 1973). After implantation of the morphine pellet, animals exhibit the characteristic signs of acute morphine effects (Wei and Way, 1975).
The acute effects of the morphine pellet largely subside withi n twenty-four hours, while the optimum time for obtaining a
tolerant and dependent state after implanting a morphine
pellet is three days (Wei and Way, 1975).

In the mouse, tol-

erance and dependence were noted to be maximum three to four
days after implanting the pellet, after which there is a decrease in these parameters because the pellet becomes encapsulated with fibrous tissue (Way et al., 1969).

Similarly,

in the rat tolerance and precipitated withdrawal signs became maximal three to five days after a single pellet implant
(Wei, 1973; Cicero and Meyer, 1973).

Dependence was maximal

three days after morphine implantation in the guinea pig
(Goldstein and Schultz, 1973).
The withdrawal syndrome is represented by a constellation of behavioral signs after pellet implantation.

The

following withdrawal signs have been observed in the rodent,
body weight loss, jumping, wet shakes, vocalizations, fighting behavior and piloerection (Wei and Way, 1975).

Most

investigators have found the abrupt withdrawal syndrome difficult to quantify because the protracted course of abstinence
requires extended periods of continuous observation after
pellet removal

(Ho et al., 1972). The delayed onset and pro-

tracted course of abrupt morphine withdrawal have led to the
increasing use of antagonist-precipitated withdrawal for the
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assessment of physical dependence.

The withdrawal syndrome

precipitated by opiate antagonists is a rapid event that appears to condense, in a short period, the abstinence signs
of abrupt withdrawal (Wei and Way, 1975).
The pellet implantation technique provides a simple
and rapid method for inducing morphine tolerance and dependence in a wide variety of laboratory animals.

However, after

a pellet is in place the daily dose of morphine cannot be
controlled directly.

Abrupt morphine withdrawal may require

surgical intervention or may not be possible.

The effective-

ness of the pellet method for inducing primary physical dependence on narcotics other than morphine has not been reported.
4.

Infusion
Recently, several investigators have demonstrated

that physical dependence on narcotics can be rapidly induced
in the rat by either continuous or discontinuous injections
of morphine solutions (Coussens et al., 1973; Teiger, 1974;
Numan et al., 1975).

A high degree of physical dependence

on morphine has been produced in the rat with two to six
days of continuous intraperitoneal infusion (Teiger, 1974).
In this model, rats are prepared with an indwelling intraperitoneal catheter, which is led out through a stab wound
in the back.

They are then fitted with a harness and al-

lowed to roam freely within their home cage by use of a
spring and swivel arrangement. The catheter is attached to
a Harvard pump, and morphine or other drugs are infused
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continuously at a slow rate (Teiger, 1974; Harris, 1976). On
abrupt withdrawal or administration of an antagonist, the
typical signs of abstinence are seen. After two days of morphine infusion (100 mg/kg/day) as little as 0.1 mg/kg of
naloxone or 1 mg/kg of nalorphine precipitated abstinence,
while after six days of morphine infusion, abrupt withdrawal
tests showed a high degree of physical dependence.

Weight

loss and hyperirritability were the signs used to follow the
time course and severity of the withdrawal syndrome (Teiger,
1974; Harris, 1976).

This method also allowed Teiger (1974)

to demonstrate physical dependence on codeine and merperidine
by abrupt withdrawal as well as precipitated withdrawal.
Harris (1976) has used this technique to study the concomitant administration of narcotics and narcotic antagonists.
Intermittent injections of morphine sulfate in increasing doses has been found to produce reliable narcotic dependence in rats

(Coussens et al., 1973; Numan et al., 1975;

Smith and Davis, 1975).

In this model rats are implanted

with an indwelling jugular catheter and fitted with a harness.
The catheter is connected by way of a swivel to an injection
system located outside the chamber (Smith and Davis, 1973;
1975; Numan et al., 1975). Discontinuation of injections resulted in the appearance of a withdrawal syndrome characterized by ptosis, piloerection, writing, body shakes, hypothermia and weight loss (Coussens et al., 1973; Numan et al.,
1975).

Rats withdrawn from these injections acquired high

rates of operant responding for morphine self-administration
(Numan et al., 1975).
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The short duration of time needed for infusion methods
to induce physical dependence on morphine as well as other
narcotics makes it a useful method.

However, surgery is re-

quired along with expensive infusion equipment.
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III
METHODS AND MATERIALS
A.

Animals
Male hooded rats of the Long-Evans strain, random-bred,

weighing 250-350 grams were obtained from Charles River Breeding Farms, Wilmington, Massachusetts.

Prior to their use in

this investigation the rats were housed in colony cages and
allowed free access to food and water at all times.
B.

Drugs
Azaperone, benperidol, haloperidol, spiramide, oxiper-

mide, spiperone, pipamperone, pimozide, fentanyl, and dexetimide were obtained through the courtesy of McNeil Laboratories,
Inc., Fort Washington, Pennsylvania and Janssen Pharmaceutica,
Beerse, Belgium.

Chlorpromazine, trifluoperazine, phenoxy-

benzamine, tranylcypromine and amphetamine were obtained
from Smith Kline and French Laboratories of Philadelphia,
Pennsylvania.

Eli Lilly and Company of Indianapolis, Indiana

supplied the methadone, propoxyphene, apomorphine and fluoxetine. The naloxone was provided by the Endo Laboratories, Inc.
of Garden City, New York.

Pilocarpine, dihydroxyphenyl-1-

alanine, atropine, scopolamine, oxotremorine, and DL-5hydroxytryptophan were purchased from the Aldrich Chemical
Company, Inc., Milwaukee, Wisconsin. Chlordiazepoxide, flurozepam, diazepam, Ro4-4602/l and physostigmine were generously
supplied by Hoffmann-La Roche, Inc., Nutley, New Jersey.
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The Merck Sharp and Dohme Company of West Point, Pennsylvania
supplied the methysergide, benztropine and amitriptyline.
The d and 1 isomers of butaclarool were supplied by the Ayerst
Laboratories of Montreal, Canada.

Loxapine was supplied by

Lederle Laboratories of Pearl River, New York.

The morphine

sulfate was purchased from the Merck Chemical Company, Rahway,
New Jersey.

Winthrop Laboratories provided the pentazorine.

Deanol was provided by the Riker Laboratories of Northridge,
California.

The Eastman Kodak Company of Rochester, New

York provided the choline chloride.

Desmethylirnipramine was

obtained from the Geigy Pharmaceutical Company of Ardsley,
New York.

The alpha-methyl-p-tyrosine was purchased from

the Sigma Chemical Company, St. Louis, Missouri.

Boehringer

Ingelheim, Ltd. of Elmsford, New York provided the clonidine.
Sodium pentabarbital was obtained from the Mallinckrodt
Chemical Works, St. Louis, Missouri.
Azaperone, benperidol, haloperidol, spiramide, oxiperrnide, pipamperone, spiperone and pimozide were dissolved
in 0.3% tartaric acid.

Alpha-methyl-p-tyrosine, L-DOPA and

DL-5-hydroxytryptophan were suspended in 0.5% carboxymethyl
cellulose.

All other drugs were dissolved in physiological

saline.
C.

Chronic Intravenous Morphine Administration
1.

Cannula Construction
The cannulas employed for chroni c intravenous in-

fusion were constructed from polyethylene and silicone tubing.

The intramedic polyethylene tubing, I.D. 0.023 in. x
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O.D. 0.0 38 in., was obtained from Clay Adams, Parsippany,
New Jersey. Silastic brand medical grade silicone tubing,
I.D. 0.020 in. x O.D. 0.037 in., was obtained from the Dow
Corning Corporation, Midland, Michigan. The polyethylene tubing was cut into 1.5 ft segments while the silicone tubing
was cut into either 0.75 in. or 1.5 in. pieces.

The two

pieces of silicone tubing were then placed in ether for 15
seconds resulting in expansion of the tubing. The polyethylene was first inserted through the 0.75 in. silicone tubing
until it was about 1 in. from the end of the polyethylene
tubing. Secondly, the 1.5 in. segment of silicone tubing was
placed about 0.25 in. over the end of polyethylene tubing
closest to the 0.75 in. silas tic piece.

The tip of the sili-

cone tubing not overlapping the polyethylene tubing was
sealed with Silastic brand medical adhesive made by the Dow
Corning Corporation, Midland, Michigan. A small amount of
silicone adhesive was also placed around the junction between
the polyethylene and silicone tubing.

The cannula was then

bent to form a U-shape in a hot water bath.

The bend was

made at the middle of the 0. 75 in .. piece of silicone tubing.
The cannulas were allowed 24 hours to dry prior to use. Many
small holes made by needle pricks were placed in the 1.5 in.
segment of silicone tubing for the drug solution to flow
through before being implanted in the jugular vein.
cannula is shown in Figure 1.

The
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FIGURE 1.

Diagram of the Cannula Employed for Chronic
Intravenous Morphine Administration
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2.

Cannula Implantation
The rats were anesthetized with 50 mg/kg of sodium

pentobarbital administered intraperitoneally.
As soon as the rat was unconscious, the back of the
neck behind the ears, the upper chest and lower neck were
shaved with small animal clippers.
was removed from these sites.

As much hair as possible

These areas were then wiped

with gauze soaked in 70% alcohol solution.
An incision was made through the skin above the right
jugular vein which is approximately 1-2 cm from the midline.
The right external jugular vein was exposed by using blunt
dissection.
A small cut was then placed in the vein through which
the cannula was inserted.

The cannula was filled with 0.9%

saline and attached to a 3 ml syringe also filled with saline.
The silicone tip of the cannula was inserted into the vein
as far as the polyethylene tubing, so that the entire 1.5 in.
segment of silicone tubing was in the vein.
then tied in the vein with silk suture.

The cannula was

Additional sutures

were employed to sew the cannula to the neck muscles.
A 10 cm sterile piece of 15 gauge stainless steel tubing with a sharpened point at one end was inserted beneath
the skin at the site of the incision.

The tubing was pushed

carefully underneath the skin until the sharpened end was
brought through the shaved skin on the rat's back.

The

cannula was then inserted into the stainless steel tubing
until it came out the other end.

The entire length of can-

nula was pulled through the tubing prior to its removal.
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The incision was then sutured closed.

The muscle was

sutured back together with absorbable sutures while silk
suture was employed to close the skin.

Following surgery

75,000 units of procaine penicillin G was injected intramuscularly in the hind paw.

The rat was then placed in a saddle.

The saddle was constructed from a small square of brass shim
stock to which a curved piece of 13 gauge hypodermic needle
tubing was soldered for the purpose of attaching a metal
spring leash. A copper wire collar for the rat's neck was
also soldered to the brass square.

A piece of VelcroR nylon

closure was cemented to the top of the saddle and a mating
Velcro

R

strap was employed to pass around the rat's thorax

just behind the forelegs.

The inner parts of both the saddle

and the strap were padded with 1/4-inch polyurethane foam.
Each rat was placed individually in plexiglass chambers for
the duration of the experiment.

The plexiglass chambers were

located in air-conditioned rooms thermostatically maintained
at 20-22° with room lighting turned off between 8 P.M. and
7 A.M. The cannula was passed from the rat's saddle through
a long metal spring to the top of the plexiglass chamber
where it was connected to an injection system located outside the chamber. This apparatus is shown in Figure 2.
3.

Injection System
The injection system consisted of a Harvard Appa-

ratus Compact Infusion Pump Model 975 which was modified to
hold 4 or 8 syringes having a 10-ml capacity.

The syringes
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FIGURE 2.

Rat Housed in Plexiglass Chamber Fitted
with Cannula and Saddle for Chronic
Intravenous Morphine Administration
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were then filled with either a solution of morphine sulfate
or normal saline which was infused according to the addiction
schedule.

D.

Addiction Procedure
The syringes in the infusion pumps were filled with

morphine sulfate and infused according to the schedule shown
in Table 1.

The starting dose of 36 mg/kg/day morphine sul-

fate was gradually increased until a terminal dose of 100
mg/kg/day was reached.

A minimum of five days on the terminal

dose of morphine was allowed before the infusion pumps were
turned off to produce withdrawal.

E.

Measurement of Withdrawal Body Shakes
Morphine withdrawal body shakes were measured 8 to 12

hours after the morphine infusion was discontinued.

The in-

fusion pumps were stopped at midnight so that the pretreatment withdrawal observation could be made at 8 A.M. the following morning.

To observe withdrawal body shakes the doors

of the plexiglass chambers were opened and food cups removed.
Each rat was observed for a period of 30 min during which
the occurrence of withdrawal body shakes were counted. Body
shakes were defined as violent shaking movements of the head
and/or trunk of the rat which resemble the action of an animal that has been drenched with water (for a description and
review, see Gianutsos et al., 1975a).

The test drug was then

injected, food cup replaced, cage door closed, and a prede-
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Table 1.

Morphine Concentration and Infusion Schedule to Establish
Morphine Dependence in the Rat

Infusion Flow Ratel

Day

Pump
Setting

ml/day

2

Morphine I nfusion/Day
Total
mg

mg/kg

1

30

1.08

12

36

2

29

1. 51

17

50

3

28

2.16

24

71

27

3.02

33

100

4-10

l.Harvard Apparatus Infusion Pump Model No. 975.
capacity.
2~Morphine

Syringes with a 10-ml

sulfate dissolved in saline at a concentration of 11 mg/ml.
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determined period for onset of drug action was allowed.

Fol-

lowing this treatment the rats were observed again for 30
min for the occurrence of body shakes, as before the cage door
was opened and food cup rennved.
After the post-drug observation the infusion pump was
turned on again to continue infusion of morphine solution until the next withdrawal.

F.

Statistical Analysis
The effectiveness of the test drug was determined by

comparing the withdrawal body shakes observed on the same day
before and after the drug treatment.
shakes served as a

~ign

Therefore, the pre-drug

of withdrawal against which the ef-

fectiveness of the test drug was evaluated.

This was accom-

plished by calculating the average number of body shakes exhibited during the pre-drug observation period by those withdrawn rats reaching criteria.

Withdrawn rats had to show a

minimum of 8 withdrawal body shakes in the 30 min. observation period to be employed for drug testing.

Criteria was

established at 8 body shakes since 97 percent of the rats
withdrawn from morphine showed this number of shakes while
only 13 percent of the rats infused chronically with saline
exhibited 8 or more body shakes.

The average number of body

shakes occurring during the pre-drug observation was then
divided into the number of withdrawal shakes observed for
each individual subject after the test drug administration.
A mean and standard error was then calculated from these
individual percentage values.
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Regression analysis was employed to test for the existence of a dose response relationship.

The Student's 't'

test was employed to establish significant differences between treatment groups,

with the level of statistical signif-

icance defined as a P value of less than 0.05.

The dose of

test drug that reduced withdrawal body shakes by 50 percent
(Io 50 ) was calculated from the regression equation Y=MX+b.
Where the slope is M and the Y intercept is b.

The equation

was then solved for X where Y was designated as 50 percent
inhibition.
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IV
RESULTS

A.

The Occurrence of Morphine Withdrawal Body Shakes
Rats implanted with indwelling cannula and perfused with

saline showed only negligible withdrawal body shakes (Table
2).

These results are in agreement with previous reports

(Numan et al., 1975; Lal and Numan, 1976).

However, termina-

tion of morphine infusion in rats who had been continuously
perfused with morphine for several days resulted in the reliable and frequent occurrence of withdrawal body shakes as
can be seen in Table 2.

These dependent rats showed an aver-

age of 25 withdrawal body shakes in a 30-min observation
period which was significantly

(p~0.001)

greater than the

number of body shakes observed in saline infused rats.

The

frequency distribution for the occurrence of withdrawal body
shakes upon the cessation of morphine or saline infusion i s
shown in Table 3.

Rats withdrawn from morphine exhibit nnre

than 8 withdrawal body shakes 97 percent of the time while
sal~ne

controls show less than 7 shakes 87 percent of the

time in a 30-min observation period.

Fifty-two percent of

the time withdrawn rats show between 8 and 21 body shakes
while only 13 percent of saline infused rats exhibited shakes
at this frequency.

More than 21 shakes were observed in the

remaining 45 percent of withdrawn rats while saline infused
rats show no shakes at this frequency •
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Table 2.

The Incidence of Withdrawal Body Shakes in Dependent and Non-Dependent Rats

Withdrawal
Body Shakes 3
(Mean + S. E.)

Chronic
1
Treatment

N2

Saline

54

2.6 + 0.5
-

Morphine

54

25.1 + 1.7*
-

1.

Intravenously infused for several days as described in
the text.

2.

The number of rats observed after specified chronic
treatment.

3.

Pretreatment withdrawal shakes were observed for a 30
min period 8 hours after the termination of morphine
or saline infusion.

*

Significantly (p J:. 0. 001) different from saline group
according to Student's "t" test, two-tailed.
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Table 3.

The Incidence of Withdrawal Body Shakes in the Rat

Percent of Rats Showing Shakes
of Stated Frequencyl
Number of
Withdrawal Shakes

Morphine
Withdrawal 2

Saline
Controls 3

0

0

44

1-7

3

43

8-14

30

9

15-21

22

4

22-28

14

0

29-35

14

0

36-42

8

0

43-49

4

0

50

5

0

.L..

1.

Withdrawal shakes were observed for a 30-min period
8 hours after the termination of morphine or saline
infusion.

2.

Based upon 505 withdrawal observations of morphine
dependent rats.

3.

Based upon 54 withdrawal observations of saline
perfused rats.
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Before initiating the drug studies it was first established that rats once made dependent upon morphine exhibited
a fairly consistent number of shakes even upon repeated withdrawal.

This information was obtained by withdrawing depend-

ent rats 12 consecutive times and observing the occurrence of
withdrawal body shakes after 8 hours of withdrawal.

At least

14 hours of morphine infusion was instituted between withdrawal observations.

The data given in Table 4 show that an

average of 18 body shakes occurred during the first withdrawal session after 5 days of maintenance at the terminal concentration of morphine.

The number of shakes was significant-

ly greater than those observed before withdrawal {p L0.0001)
or those observed in rats withdrawn from saline infusion
{pL'.0.001).

The rate of withdrawal body shakes was somewhat

higher on day 3 and then remained fairly constant throughout
the period of consecutive withdrawal trials until the experiment was terminated after completion of 12 withdrawal observations.

B.

The Effect of Narcotics on Morphine Withdrawal Body
Shakes
1.

The Effect of Narcotic Agonists
Upon the termination of morphine infusion, withdraw-

al body shakes began to occur within 3 hours but were not
fully developed until 6 hours after which time they remained
constant for up to 24 hours if the morphine infusion was not
reinstated.

The administration of morphine, methadone or

fentanyl, potent narcotic agonists, reliably abolished the
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Table 4.

Withdrawal
Sessions

The Frequency of Withdrawn Body Shakes During
Twelve Consecutive Withdrawal Sessions

1
N2

Withdrawal Shakes 3
(Mean + S. E.)

1

36

18.3 + 1.4
-

2

29

20.0 + 1.5

3

22

24.7 + 3.1
-

4

18

25.3 + 4.6
-

5

16

27.9 + 4.3

6

15

24.5 + 3.2

7

12

26.8 + 4.7
-

8

13

25.7 + 3.1
-

9

12

24. 6 + 3.5
-

10

11

32.2 + 3.6
-

11

10

27.4 + 3.3
-

12

8

25.3 + 4.5

1.

Dependent rats were withdrawn on 12 consecutive days.
Withdra wa l shakes were counted after 8 hours of withdrawal . At least 14 hours of morphine infusion were
instituted between withdrawal observation sessions.

2.

The number of rats observed during each withdrawal
session.

3.

Withdrawal shakes were observed for a 30-min period
8 hours after the termination of morphine infusion.
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occurrence of withdrawal body shakes 8 hours after the termination of morphine infusion.

These results are summarized in

Table 5 which shows that the regression coefficient for each
of these narcotics was significant (p L. 0. 05) .
ID

50

Calculation of

concentrations on a mg/kg basis revealed fentanyl to be

the most potent with methadone being the next most potent and
morphine having the lowest potency for those narcotics tested.
2.

The Effect of Narcotic Antagonist
The injection of either naloxone or pentazocine 8

hours after the cessation of morphine infusion did not cause
any further increase in the rate of withdrawal shakes as is
shown in Table 5.

There was a slight tendency towards an in-

crease in the number of withdrawal body shakes, however, this
increase was not significant.
3.

The Interaction Between Narcotics and Naloxone
Morphine (40 mg/kg) administration reduced with-

drawal body shakes by about 90 percent.

Naloxone antagonizes

this morphine-induced blockade of withdrawal shakes in a dose
dependent manner (Table 6).

A naloxone dose of 1.25 mg/kg

completely reversed the blockade produced by morphine given
at a dose of 40 mg/kg.

Increasing the naloxone dose to 5

mg/kg did not increase the withdrawal shakes beyond those
seen before morphine injection.

C.

The Effect of Dopaminergic Agents on Morphine Withdrawal
Body Shakes
1.

The Effect of Dopaminergic Antagonists
The effect of the various dopaminergic antagonists

The Effect of Narcotic Agonist and Antagonist on Morphine Withdrawal Body Shakes

Table 5.

Treatment

1

Dose
(mg/kg)

Saline
Fentanyl

Methadone

Morphine
Naloxone

Pentazocine

0.04
0.16
0.64
2.5
2.5
10
40
10
40
0.16
0.64
1.25
5.00
10
40

N2

Withdrawal Shakes
.% Pretreatment
(Mean ~ S.E.) 3

ID50
(m~j/kg)

Correlation
Coefficient

64

110.2 +

5
16
6
6

116.4 + 70.0
107.0 + 22.7
4.8
4.8
0 + 0
-

0.3

-0.88*

7
8
5

53.4 + 14.4
9.4
14.7
0 + 0

4.1

-0.96*

14
10

67.6 + 21.7
11.6 + 5.0

14.4

-0.99*

5
8
11
8

169.8 + 43.9
112.4 + 26.5
128.6 + 11.4
105.1 + 14.5

-

-

-0.33

6
5

111.5 + 36.9
133.4 + 52.1

-

+0.88

-

9.6

+

+
-

-

l."All drugs were administered i.p. 30 min prior to observation with the exception of fentanyl and naloxone which were given 10 mins prior to post treatment observation.
2.The number of rats employed per dose.
3.Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of morphine
ab s tinence.

*Significant

I-'

(p..L.0.05) regression coefficient.

0
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Table 6.

Naloxone
(mg/kg)

Reversal of Morphine Induced Blockade of Withdrawal Body Shakes by Naloxone

1
N2
10

0

Withdrawal Shakes
% Pretreatment
(Mean+ S.E.)3
11.6 +

-

Correlation
Coefficient

5.0

0.04

7

23.8 + 11.7

0.16

7

65.0 + 13. 9

0.64

8

49.3 + 17.5

1.25

8

86.3 + 13. 4

5.00

8

97.8 + 32.0

-

-

-

+0.93*

1.

Morphine sulfate (40 mg/kg) was administered i.p. to all
rats 30 min prior to post treatmenu observation.
Naloxone was then injected i.p. 20 min after the morphine
administration which was 10 min prior to observation.

2.

The number of rats employed per dose.

3.

Pretreatment withdrawal body shakes were observed for
a 30 min period after 8 hours of morphine abstinence.

*

Significant regression coefficient (P.L0.05).
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test on withdrawal shakes are shown in Tab le 7.

Benperidol

dose dependently reduced withdrawal shakes and this effect
was significant (r

=

0.93, p.L...0.05) by regression analysis.

A dose of 0.01 mg/kg of benperidol was without effect but increasing the dose to 0.64 mg/kg reduced withdrawal body shakes
by 95 percent.

(+)Butaclamol produced a dose dependent re-

duction in body shakes with a dose of 0.64 mg/kg reducing
shakes b y approximately 80 percent.

The correlation coef-

ficient for the relationship between the log dose of (+)butaclamol and percent reduction in body shakes was (r
p~0.05).

=

0.98,

(-)Butaclamol did not reduce withdrawal shakes.

The phenothiazine neuroleptic, chlorpromazine, at a dose of
0.16 mg/kg reduced shakes to 50 percent of pretreatment. The
degree of reduction remained at approximately 50 percent even
when the dose of chlorpromazine was increased to 0.64 or
2.5 mg/kg.

However, further increasing the dose to 10 mg/kg

did completely reduce the occurrence of withdrawal shakes.
The correlation coefficient for chlorpromazine (r

=

0.83) was

not significant suggesting that the effect was not dose dependent.

Haloperidol reduced withdrawal shakes in a dose

dependent manner.

A reduction of 80 percent was achieved by

the administration of haloperidol at a dose of 0.64 mg/kg.
Regression analysis demonstrated a significant (r
p~0.05)

dose effect relationship.

=

0.98,

The dopamine antagonist

loxapine produced a similar reduction in withdrawal body
shakes.

A near total blockade of withdrawal shakes was

achieved by the administration of 2.5 mg/kg of loxapine.

Table 7.

Treatment

1

Saline
Benperidol

+Butaclamol

-Butaclamol
Chlorpromazine

Haloperidol

Loxapine

Oxiperomide

The Effect of Various Neuroleptics on Morphine Withdrawal Body Shakes

Dose
(mg/kg)

N2

--

Withdrawal Shakes
% Pretreatment
(Mean + S • E. ) 3

ro5o
(mg/kg)

Correlation
Coefficient

-

64

110.2 +

0.01
0.04
0 .1 6
0.64

15
8
12
5

116.1 + 15.7
48.5 + 13.2
50.8 + 6.8
4.8 + 3.7

0.08

-0.93*

0.04
0.16
0.64

4
7
7

66.2 + 18.6
40.2 + 10.8
21.1 + 7.7

0.12

-0.98*

0.64

9

128.4 + 14.2

0.16
0.64
2.50
10.00

12
4
5
2

45.7 + 10.5
25.2 + 20.0
50.4 + 15. 7
0 + 0

0.49

-0.83

0.04
0.16
0.64

9
8
13

83.4 + 14.8
41.5 + 9.5
5.3
19 . 4 +
-

0.17

-0.98*

0.04
0.16
0.64
2.50

6
9
7
9

53.8 + 7.2
38.8 + 13.6
44.7 + 17.9
0. 8 + 0.5

0.16

-0.92*

0.14
0.16
0.64
2.50

7
9
9
10

90.0 + 19.l
30. 0 + 7.7
18. 2 + 6.1
3.8 + 2.2

-

9.5

-

-

-

......
0
00

0.16

-0.96*

Table 7 (continued)
Pimozide

Pipamperone

Spiperone

Spiramide

Trifluoperazine

0.04
0.16
0.64
2.50

7
7
12
13

55.5 + 16.4
68.1 + 23.4
82.7 + 18.7
35.8 + 12.2

1.64

-0.68

2.50
10.00
40.00

6
5
4

38.6 + 13.2
79.8 + 14.4
22.2 + 14.5

11.02

-0.71

0.01
0.04
0.16
0.64

10
9
7
15

72.0 + 14.3
50.2 + 16.9
22.0 + 11.3
14.7 + 5.2

0.04

-0.97*

0.04
0.16
0.64
2.50

6
7
9
6

0.19

-0.98*

0.16
0.64
2.50
10.00

3
6
4
5

0.74

-0.97*

-

-

82.6 + 22.5
43.5
34.5
0. 6

+ 9.3
+ 16.8
-+ 0.6

80.3 + 15.1
36.3 + 14.6
38.7 + 29.6
0 +0

l.All drugs were administered i.p. 30 min prior to observation with the exception of
haloperidol and pirnozide which were given 120 min prior to post-treatment observation.
2.The number of rats employed per dose.
3.pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.
*Significant regression coefficient (p.O:::: 0.05).
......
0
\0
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Dose effect analysis demonstrated a significant (r
p~0.05)

correlation coefficient.

=

0.92,

A dose dependent reduction

in withdrawal body shakes was also produced by the administration of oxiperomide.

Withdrawal shakes were reduced by 95

percent by the administration of oxiperomide at a dose of
2.5 mg/kg.
(r

=

Regression analysis revealed a significant

0.96, p.L 0.05) correlation coefficient.

Pimozide did

not reduce withdrawal body shakes in a dose dependent manner.
Even with highest dose employed, 2.5 mg/kg, withdrawal shakes
were only reduced by approximately 65 percent.

Pipamperone

failed to reduce withdrawal body shakes in a dose dependent
manner (r

=

0.71).

A dose of 2.5 mg/kg reduced shakes by 60

percent; however, when the dose was increased to 10 mg/kg
the reduction was only 20 percent. Withdrawal shakes were reduced by 80 percent when a 40 mg/kg dose of pipamerone was
employed.

Spiperone did reduce the frequency of withdrawal

shakes in a dose related fashion.

At a dose of 0.04 mg/kg

spiperone reduced shakes by about 50 percent while increasing
the dose to 0.64 mg/kg reduced shakes by 85 percent.

The

correlation coefficient for the relationship between the
log dose of spiperone and percent reduction in body shakes
was significant (r

=

0.97, p..L 0.05).

A similar dose related

decrease in the frequency of withdrawal shakes was produced
by the administration of the neuroleptic spiramide.

A total

reduction in shakes was achieved when sipramide was administered at a dose of 2.5 mg/kg. Regression analysis show a
significant (r

=

0.98,

p~0.05)

correlation coefficient.
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Trifluoperazine, a phenothiozine neuroleptic, also reduced
withdrawal shakes but only at relatively high doses.

A 10

mg/kg dose of trifluoperazine was needed to completely abolish the occurrence of withdrawal body shakes.

The dose de-

=

pendent effect was found to be significant (r

0.97, pL0.05)

by regression analysis. Consideration of the ID

values for
50
these neuroleptics showed that on a mg/kg basis the order
of potency for those neuroleptics tested to be as follows:
spiperone, benperidol, +butaclamol, loxapine, oxiperomide,
haloperidol, spiraimide, chlorpromazine, trifluoperazine,
pimozide and pipamperone.
2.

The Effect of Dopaminergic Agonists.
The dopaminergic agonists tested for their effects

on withdrawal shakes all reduced shakes as can be seen in
Table 8.

Amphetamine produced a dose-related decrease in

the frequency of withdrawal shakes which was significant
(r

=

0.96, p.L0.05) by regression analysis.

When a 2.5

mg/kg dose of amphetamine was employed shakes were reduced
by 85 percent.

In a similar fashion withdrawal shakes were

dose dependently reduced by the dopaminergic agonist, apomorphine.

A 95 percent reduction was demonstrated when

apomorphine was given at a dose of 0.64 mg/kg.

The corre-

lation coefficient for the dose-effect relationship was
(r

=

0.99, pL0.05).

The administration of L-DOPA also pro-

duced a dose dependent reduction in withdrawal shakes.
lysis of the L-DOPA effect demonstrated a significant

Ana-

Table 8.

Treatment

1

Dose
(mg/kg)

Saline
Amphetamine

Apomorphine

L-DOPA

4

Reduction of Morphine Withdrawal Body Shakes Induced by
Dopamine Receptor Stimulants

N2

-

64

Withdrawal Shakes
% Pretreatment
(Mean + S. E. ) 3
110.2 +

106.3 + 24.4
53.6 + 11.9
20.7 + 4.6
13. 0 + 6.0

7
8
8
9

0.01
0.04
0.16
0.64

3
5
7
8

49.2
35.3
5.0

+

9
6
5

41.0
23.2

+ 14.4

10.0
40.0
160.0

86.6 + 28.1

13.9
8.7
2.5

-+
66.6 + 17.3

+

Correlation
Coefficient

9.6

0.04
0.16
0.64
2.50

+

ID50
(mg/kg)

0.26

-0.96*

0.06

-0.99*

32.47

-0.97*

20.9

l.All drugs were administered i.p. 30 mins prior to observation with the exception of apomorphine which was given 10 mins prior to post-treatment observation.
2.The number of rats employed per dose.
).Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of morphine
abstinence.
4. These rats were injected with 25 mg/kg of R04-4602/l 30 mins prior to L-DOPA administration.
*significant regression coefficient (pL.0.05).
f--'
f--'
l\J

113

(r

= 0.97;

p.L0.05) correlation coefficient.

The

ro 50

values

for amphetamine, apomorphine and L-DOPA were 0.26, 0.06 and
32.47 mg/kg, respectively.
3.

The Interaction Between Dopaminergic Agents and

Naloxone
When administered after a large dose of haloperidol,
naloxone caused a considerable reversal of the haloperidol
effect in blocking withdrawal shakes as can be seen in Tables
9 and 10.

Haloperidol in a dose of 0.64 mg/kg reduced body

shakes to 20 percent of pretreatment but when administered in
conjunction with naloxone body shakes were reduced to only
about 50 percent of pretreatment.

Naloxone, at a dose of

0.64 mg/kg produced a maximum effect which could not be further potentiated by increasing the naloxone dose to 5 mg/kg.
However, only the 5 mg/kg dose of naloxone produced an effect which was significantly

(p~

0.05) different from halo-

peridol alone (Table 10).
The data summarized in Table 10 show the interaction
between the various neuroleptics found to reduce withdrawal
body shakes and naloxone.

The maximum effect dose of each

neuroleptic was combined with a 5 mg/kg dose of naloxone.
Benperidol, oxipermide, haloperidol and trifluoperazine were
the only neuroleptics to have their effects significantly
(p..oi::0.05) antagonized by the administration of naloxone
(5 mg/kg).

The interaction between benperidol and naloxone

proved to be significant

(p~0.002)

in that benperidol

alone (0.64 mg/kg) reduced withdrawal shakes by 95 percent
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Table 9.

Naloxone 1

The Effect of Naloxone on the Haloperidol
Induced Reduction in Morphine Withdrawal
Body Shakes

Withdrawal Shakes 3
% Pretreatment
(Mean + S • E. )

(mg/kg)

N2

0

13

0.64

9

45.5 + 11.5

1.25

9

35.5 +

-

9.7

5.00

8

45.0 +

9.7

19.4 +

-

Correlation
Coefficient

5.3

-

-

+0.77

1.

Haloperidol (0.64 mg/kg) was administered i.p. to all rats
120 mins prior to post treatment observation. Naloxone
was then injected i.p. 10 mins prior to observation.

2.

The number of rats employed per dose.

3.

Pretreatment withdrawal shakes were observed for a 30
min period after 8 hours of morphine abstinence.
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Table 10. The Interaction Between Neuroleptics and Naloxone
on Morphine Withdrawal Body Shake s

Withdrawal Shakes 2
% Pretreamtnet
(Mean + S. E. )
1

Treatment

Dose
(mg/kg)

Saline3
110.2 +

Saline

Naloxone3

9.6 (64)

105.1 + 14.5 (8)

Benperidol

0.64

4.8 +

3.7 (5)

60.0 +

7.9 (8)*

+Butaclamol

0.64

21 . 2 +

7. 7 ( 7)

29.4 +

5.2 (5)

10.00

0 +

( 2)

5.3 +

5.3 (3)

Haloperidol

0.64

19.4 +

Loxapine

2.50

0.8 +

0.5 (9)

Oxiperomide

2.50

3.8 +

2.2

Spiperone

0.64

14.7+

Spiramide

0.64

34.5 + 16.8 (9)

Chlorpromazine

Trifluoperazine

10.00

0.3 +

0

5.3 (13)

45.0 +
8.3 +

9.7 (8)*
4.9

(6)

(10)

18.9 +

6.8 (10)*

5.2 (15)

28.1 +

8.4

48.8 +

8.2 (10)

19.6 +

7.3 (16)*

0.3 (5)

(10)

1.

All drugs were a dministered i.p. 30 mins prior to observation with the exception of haloperidol which was given 120
mins prior to post treatment observation.

2.

Pretreatment withdrawal shakes were observed for a 30 min
period after 8 hours of morphine abstinence.

3.

Saline or naloxone (5 mg/kg) was administered 10 mins prior
to observation.

4.

The number of rats employed per dose is indicated in
parentheses.

*

Significantly (p.L0.05) different from saline by Student's
't' test.
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but when administered in conjunction with naloxone (5 mg/kg)
body shakes were reduced by only 40 percent.

Naloxone

failed to antagonize the effects of spiperone, spiramide,
loxapine, chlorpromazine and +butaclamol to any significant
extent.
The data obtained when naloxone was administered in
conjunction with dopaminergic agonist is shown in Table 11.
The effect of apomorphine was significantly (p...t!.0.05) antagonized by the administration of naloxone (5 mg/kg).

However,

the administration of naloxone in conjunction with amphetamine failed to produce any significant antagonism of the
amphetamine effect.

D.

The Effect of Adrenergic Agents on Morphine Withdrawal

Body Shakes
1.

The Effect of Adrenergic Antagonist
The data in Table 12 demonstrates a block ade of

withdrawal shakes by azaperone, a butyrophenone neuroleptic
possessing high alpha noradrenergic potency.
azaperone was significantly (r

=

The effect of

0.96, pL0.05) dose depend-

ent by regression analysis with a dose of 0.64 mg/kg reducing body shakes by about 95 percent.

The alpha noradrenergic

blocker phenoxybenzamine failed to produce any significant
effect on withdrawal body shakes. Similarly, the beta
blocker propronalol also failed to reduce withdrawal shakes
to any significant extent.

A dose of 10 mg/kg of propronalol

only reduced shakes by about 30 percent.
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Table 11.

The Interaction Between Dopamine Receptor
Stimulants and Naloxone on Morphine Withdrawal
Body Shakes

Withdrawal Shakes
% Pretreatment
(Mean + S. E.)
Treatment

1

Dose
(mg/kg)

Saline

Saline 3
110.2 +

9.6 (64)

Amphetamine

2.50

13.0 +

6.0 (9)

Apomorphine

0.64

5.0 +

2.5 (8)

2

Naloxone 3
105.1 + 14.5 ( 8)
2.5 +

1.6 (8)

43.3 + 17.1 ( 6)

*

1. All drugs were administered i.p. 30 mins prior to observation with the exception of apomorphine which was given 10
mins prior to post treatment observation.
2. Pretreatment withdrawal shakes were observed for a 30 min
period after 8 hours of morphine abstinence.
3. Saline or naloxone (5 mg/kg) was administered 10 mins
prior to observation.
4. The number of rats employed per dose is indicated in
parentheses.

*

Significantly (pL0.05) different from saline by Student's
't' test.

Table 12.

1
Treatment

The Effect of Adrenergic Blockers on Morphine Withdrawal Body Shakes

Dose
(mg/kg)

64

Saline
Azaperone

Phenoxybenzamine

Propranolol

N2

--

Withdrawal Shakes
% Pretreatment
(Mean + S. E. ) 3

--

110.2 +

ID50
(mg/kg)

Correlation
Coefficient

9.6

0.01
0.04
0.16
0.64

4
7
6
13

78.7 + 15.3
33.1
15.9
10.6 + 8.9
7.8 + 3.2

0.64
2.5
10.0

7
20
9

51.9
68.5

2.5
10.0

10
6

89.2 + 11.8
70.0
13.1

+

74.4 + 14.8

+ 11.2
-+ 16.1
+

0.04

-0.96*

8.66

-0.76

38.45

-0.99*

1.

All drugs were administered i.p. 30 mins prior to post treatment observation.

2.

The number of rats employed per dose.

3.

Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.

*

Significant regression coefficient (pL..0.05).

I-'
I-'
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2.

The Effect of Adrenergic Agonist
The adrenergic agonist amitriptyline, clonidine, des-

methylimipramine and tranylcypromine were tested for their effects on withdrawal body shakes.

The effect of these agents

on body shakes are shown in Table 13. Desmethylimipramine
(r

=

0.98, p.L0.05) and clonidine (r

=

0.95,

p~.05)

pro-

duced dose dependent decreases in morphine withdrawal body
shakes which were significant.

Clonidine proved to be very

effective in that a dose of 0.16 mg/kg completely abolished
the occurrence of withdrawal body shakes.

Amitriptyline and

tranylcypromine also reduced body shakes to a limited extent,
regress~on

analysis show no significant correlations between

dose and effect. Clonidine had an

ro 50

value of 0.02 mg/kg

while the value for desmethylimipramine was considerably
higher, 1.74 mg/kg.
3.

The Interaction Between Adrenergic Agents and Naloxone
The administration of naloxone after azaperone

(0.64 mg/kg) caused a considerable reversal of the azaperone
effect in reducing withdrawal shakes as can be seen in Tables
14 and 15.

Azaperone when administered at a dose of 0.64

mg/kg reduced body shakes by 95 percent but when administered
in conjunction with naloxone body shakes were reduced by only
about 40 percent. A dose of 0.64 mg/kg of naloxone produced
a maximum effect which could not be further potentiated by
increasing the naloxone dose to 5 mg/kg (Table 14). The effects of azaperone were significantly (p-'0.01) antagonized
by the administration of naloxone at a dose of 5.0 mg/kg

Table 13.

Treatment

1

The Effect of Adrenergic Agonists on Morphine Withdrawal Body Shakes

Dose
(mg/kg)

Saline
Amitriptyline
Clonidine

Desmethylimiprarnine

Tranylcypromine

2.5
10.0

N2

-64
4
6

Withdrawal Shakes
% Pre t reatment
(Mean + s . E . ) 3

1050
(mg/kg)

Correlation
Coefficient

110.2 +

- 9.6
50.3 + 14.4
49.6 + 13.9
44.1 + 8.6

6.13

-0.87

0.01
0.04
0.16

10
6

22.3
0

8.1
0

0.02

-0.95*

0.64
2.5
10.0

8
8
7

78.7 + 13.8
30.2 + 11.2
13. 7 + 4.7

1.74

-0.98*

2.5
10.0

9
8

22. 0

9.9
8.0

3.16

-0.94

6

+
+

40.0 +

+

1.

All drugs were administered i.p. 30 mins prior to post treatment observation.

2.

The number of rats employed per dose.

3.

Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.

*

Significant regression coefficient (p40.05).
.......
N
0
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Table 14.

Naloxone

1

Reversal of Azaperone Induced Blockade of Withdrawal Body Shakes by Naloxone

N2

Withdrawal Shakes
% Pretreatment
(Mean + S .E.} 3

7.8 -+

0

13

0.64

7

61.2 + 16.3

1.25

8

52.5 + 25.9

5.00

8

71.6 + 21.3

Correlation
Coefficient

3.2

-

-

+0.88

1.

Azaperone (0.64 mg/kg} was administered i.p. to all rats
30 mins prior to post treatment observation. Naloxone
was then injected i.p. 20 mins after the azaperone administration which was 10 mins prior to observation.

2.

The number of rats employed per dose.

3.

Pretreatment withdrawal body shakes were observed for a
30 min period after 8 hours of morphine abstinence.

122

Table 15.

The Interaction Between the Adrenergic Agonist :
Clonidine and the Narcotic Antagonist Naloxone
on Morphine Withdrawal Body Shakes

Withdrawal Shakes
% Pretreatment
(Mean+ S.E.)2
Treatment

1

Dose
(m9/kg)

Saline

Saline

3

Naloxone

110.2 +

-

9.6

(64)

4

3

105.1 + 14.5 (8)

-

Azaperone

0.64

7.8 +

3.2

(13)

81.6 + 21.3 (8)
-

Clonidine

0.16

o.o

o.o

(6)

12.3 +

+

-

-

4.1

*

(11)

1.

All drugs were administered i.p . 30 mins prior to post
treatment observation.

2.

Pretreatment withdrawal shakes were observed for a 30
min period after 8 hours of morphine abstinence.

3.

Saline or naloxone (5 mg/kg) was given 10 mins prior
to post treatment observation.

4.

The number of rats employed per dose is indicated in
parentheses.

*

Significantly (p.£0.01) different from saline by Student's
' t ' test.
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(Table 15).

The antiwithdrawal effect of clonidine was also

reduced by the administration of naloxone at a dose of 5 mg/kg.
These data are shown in Table 15.

The naloxone antagonism of

the clonidine effect was not nearly as large as the naloxone
antagonism of azaperone.

E.

The Effect of Agents that Influence the Synthesis and

Storage of Catecholamines on Morphine Withdrawal Body Shakes
The results achieved with alpha-methyl-p-tyrosine and
reserpine are given in Table 16.

Alpha-methyl-p-tyrosine, an

inhibitor of catecholamine synthesis, reduced withdrawal
shakes only when a dose of 160 mg/kg was employed.

Regres-

sion analysis failed to reach significance for this effect.
Reserpine, which interferes with the storage of catecholamines,
dose-dependently reduced withdrawal body shakes.

A dose of

10 mg/kg of reserpine reduced shakes by approximately 60 percent.

Regression analysis show a significant (r = 0.96,

pL.0.05) dose effect relationship for reserpine.

F.

The Effect of Serotoninergic Agents on Morphine Withdraw-

al Body Shakes
The data for the effect of serotoninergic agents on
withdrawal body shakes is shown in Table 17.

Fluoxetine,

which increases the concentration of serotonin at its receptor site by blocking its uptake,reduced body shakes by 50
percent at a dose of 0.64 mg/kg.

This effect could not be

further intensified by increasing the dose to 2.5 mg/kg.
administration of 5-HTP was similarly without significant

The

Table 16.

Treatment

The Effect of Agents that Influence the Synthesis and Storage of
Catecholamines on Morphine Withdrawal Body Shakes

1

Dose
(mg/kg)

Saline
Alpha-methyl-p-Tyrosine
Reserpine

N2

-64

40
160
0.16
0.64
2.50
10.0

6
5
8
8
10
10

Withdrawal Shakes
% Pretreatment
(Mean ~ S • E. )

ro5o
(mg/kg)

Correlation
Coefficient

110.2 +

- 9.6
91.3 + 16.9
50.6 +
- 19.7
84.5 + 16.5

53.0
48. 5
37.7

+
+
+

12.6
9.0
12.4

189.6

2.2

-0.97

-0.96*

1. All drugs were administered i.p. 60 mins prior to observation with the exception of
alpha-methyl-p-tyrosine which was given 120 mins prior to post treatment observation.
2. The number of rats employed per dose.
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.

*

Significant regression coefficient (p..:..0.05).

I-'
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Table 17. The Effect of Serotoninergic Agents on Morphine Withdrawal Body Shakes

Treatment

1

Dose
(mg/kg}

5-HTP 4

Methysergide

-

64

Saline
Fluoxetine

N2

Withdrawal Shakes
% Pretreatment
(Mean+ S.E.)3
110.2 +
-

Correlation
Coefficient

9.6

0.64
2.50

6
7

51.8 + 7.1
63.0 + 17.7

-0.76

2.50
10
40

6
7
8

153.2 + 25.5
128.0
24.9
88.6 + 37.5

-

-0.43

0.64
2.50

4
6

105.2 + 32.1
81.6 + 27.1

-0.93

-

+

1. All drugs were administered i.p. 30 mins prior to post treatment observation.
2. The number of rats employed per dose.
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
roorphine abstinence.
4. These rats were injected with 25 mg/kg of R04-4602/l 30 mins prior to 5-HTP administration .

.......
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effect on the frequency of withdrawal body shakes.

At a dose

of either 2.5 or 10 mg/kg of 5-HTP there was a slight increase in withdrawal body shakes.

Methysergide, a serotonin

antagonist, was without effect on the occurrence of withdrawal body shakes at the doses tested.

G.

The Effect of Cholinergic Agents on Morphine Withdrawal

Body Shakes
1.

The Effect of Anticholinergic Agents
Atropine, benztropine, dexetimide and scopolamine,

all well established anticholinergic drugs, were tested for
their effects on morphine withdrawal body shakes.

The data

for these anticholinergic agents are summarized in Table 18.
Atropine at a dose of 2.5 mg/kg had no effect on body shakes,
however, increasing the dose to 10 mg/kg resulted in a slight
but nonsignificant increase in the intensity of withdrawal
shakes.

Benztropine was without significant effect on with-

drawal body shakes at those doses tested.

No significant

result was achieved for the effect of dexetimide on withdrawal shakes.

However, there was a slight increase in shake

frequency at a dexetimide dose of 0.64 mg/kg.

Similarly,

scopQlamine was without significant effect on withdrawal
body shakes.

Although at a dose of 0.64 mg/kg scopolamine

did increase withdrawal shakes to 169 percent of pretreatment, this effect failed to achieve significance.
2.

The Effect of Cholinergic Agonist
A number of cholinergic agonist were studied for

Table 18.

Treatment

1

The Effect of Anticholinergics on Morphine Withdrawal Body Shakes

Dose
(mg/kg)

Benztropine
Dexetimide

Scopolamine

--

Correl a tion
Coefficient

64

110.2 +

2.5
10.0

15
9

97.8 + 20.0
132.1
23.7

-0.63

2.5
10.0

8
8

109.6 + 12.7
90. 0· + 19 .1

-0.88

0.04
0.16
0.64
2.50

7
7
5
6

93.6 + 15.6
96.6 + 20.3
8.0
140.6
118.3 + 12.8

+0.52

0.16
0.64

7
8

75.4 + 30.8
169.1
36.8

+0.62

Saline
Atropine

N2

Withdrawal Shakes
% Pretreatment
(Mean + S . E. ) 3

-

9.6

+

-

+
-

+

1.

All drugs were administered i.p. 30 mins prior to post treatment observation.

2.

The number of rats employed per dose.

3.

Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.

......
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their effect on body shakes and the results from these studies
are summarized in Table 19. Deanol and choline chloride produced decreases in withdrawal body shakes, however, regression
analysis failed to show significance.

The calculated

rn 50

values for deanol and choline chloride were 1,016 and 86 mg/kg
respectively.

Oxotremorine failed to have any significant

effect on the occurrence of withdrawal shakes.

The

rn 50

for

oxotremorine was calculated from the regression line to be
23 mg/kg which is well above the lethal dose for this drug.
A significant dose-effect relationship was established by
regression analysis for physostigmine (r
pilocarpine (r

=

0.99,

p~0.05).

The

=

rn 50

0.99, p.L0.05) and
values for physo-

stigmine and pilocarpine, 0.1 and 3.8 mg/kg, respectively,
were well within the pharmacological range of these drugs.
Pilocarpine at a dose of 10 mg/kg reduced withdrawal shakes
by 90 percent; this was the largest reduction in body shakes
produced by any of the cholinergic agonists.
3.

The Interaction Between Cholinergic Agents and

Naloxone
A 10 mg/kg dose of pilocarpine which reduced withdrawal shakes by 90 percent was i n teracted with a 5 mg/kg
dose of naloxone. The results of this interaction are given
in Table 20 .

Naloxone failed to antagonize the pilocarpine

induced decrease in withdrawal body shakes.

This is evi-

denced by the fact that withdrawal body shakes were still
reduced by 90 percent after the administration of both pilocarpine and naloxone.

Table 19. The Effect of Cholinergic Agonists on Morphine Withdrawal Body Shakes

Treatment

1

Dose
{mg/kg)

Choline Chloride

Oxotremorine

Physostigmine
Pilocarpine

64

Saline
Deanol

N2

Withdrawal Shakes
% Pretreatment
{Mean + S. E.) 3

640
2560

4
5

10
40
160

6
6
7

ID50
{mg/kg)

Correlation
Coefficient

110.2 +

- 9.6
57.7 + 16.5
25.2 + 11.4
82.2 + 17.6

42.3 + 7.6
54.7 + 12.3

93.0 + 43.l

1,016.6

-0.98

86.7

-0.88

23.3

-0.84

0.04
0.16
0.64

5
5
14

0.04
0.16

6
5

72.6 + 7.7
39.6
11.3

+
-

0.10

-0.99*

5
7

76.2 + 15.7
9.7 + 4.8

3.87

-0.99*

2.5
10.0

101. 4
75.l

+

21. 3

+
- 24.2

1. All drugs were administered i.p. 30 mins prior to observation with the exception of
oxotremorine and physostigmine which were given 10 mins prior to post treatment
observation.
2. The number of rats employed per dose.
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.

*

Significant regression coefficient {p.£0.05).

I-'
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Table 20. The Interaction Between Pilocarpine and Naloxone
on Withdrawal Body Shakes

Withdrawal Shakes
% Pretreatment
(Mean + S. E. )
Treatment1

Dose
(mg/kg)

~

110.2 + 9.6 (64)

Saline
Pilocarpine

Saline

10

9.7 + 4.7 (7)

2

Naloxone
105.1 + 14.5 (8)
9.1 +

4.5 (7)

1.

All drugs were administered i.p. 30 mins prior to post
treatment observation.

2.

Pretreatment withdrawal shakes were observed for a 30
min period after 8 hours of morphine abstinence.

3.

Saline or naloxone (5 mg/kg) was administered 10 rnins
prior to observation.

4.

The number of rats employed per dose is indicated in
parentheses.
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H.

The Effect of Gabaminergic Agents on Morphine Withdrawal

Body Shakes
The effectsof bicuculline, depakene and picrotoxin, on
morphine withdrawal body shakes are shown in Table 21.

Bi-

cuculline tested at doses of 0.16 and 0.64 mg/kg was without
effect on withdrawal body shakes.

A biphasic effect was ob-

served on withdrawal shakes after the administrat ion of depakene.

A slight reduction in shakes was observed when depakene

was administered in doses between 2.5 and 40 mg/kg; however,
as the dose was further increased to 160 or 320 mg/kg, withdrawal shakes increased in frequency.

The highest dose em-

ployed, 640 mg/kg, yielded a 60 percent decrease in withdrawal shakes.

Picrotoxin, a blocker of

J"

-arninobutyric

acid (GABA) at post-synaptic receptors, reduced the frequency
of body shakes by about 70 percent at a dose of 0.64 mg/kg.
Further increasing the dose of picrotoxin to 2.5 mg/kg was
lethal in those rats tested.

I.

The Effect of Sedative-Hypnotic Agents on Morphine

Withdrawal Body Shakes
The data sununarized in Table 22 show the effect of the
sedative-hypnotic agents tested on withdrawal body shakes.
Chlordiazepoxide had no effect on withdrawal shakes at either
2.5 or 10 mg/kg.

When the dose was increased to 40 mg/kg

there was a near total reduction in body shakes.
achieved with

flurazepam were similar.

The results

A dose of 40 mg/kg

of flurazepam was necessary to reduce withdrawal body shakes

Table 21.

Treatment

1

The Effect of Gabaminergic Agents on Morphine Withdrawal Body Shakes

Dose
(mg/kg)

Saline
Bicuculline
Depakene

Picrotoxin

N2

64

0.16
0.64
2.5
10.0
40.0
160.0
320.0
640.0
0.64
2.50

Withdrawal Shakes
% Pretreatment
(Mean .:!:_ S . E. ) 3
110.2 +

-

Correlation
Coefficient

9.6

7
6

99.8 + 41.0
124.8 + 57.3

+0.55

8
19
8
5
9
6

66.4 + 19.2
42 .2 + 9.2
76.6 + 17.4
113.0 + 31.4
280.2 + 64.7
39. 8 + 34. 7

+0.28

8
2

33.4 + 12.6
lethal

-

-

1. All drugs were administered i.p. 30 mins prior to observation with the exception of
picrotoxin which was given 15 mins prior to post treatment observation.
2. The number of rats employed per dose.
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.
I-'
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Table 22.

Treatment

1

The Effect o f Sedative-Hypnotic Agents on Morphine Withdrawal Body Shakes

Dose
(mg/kg)

Flurazepam

Pentobarbital

-64

Saline
Chlordiazepoxide

N2

2.5
10.0
40.0

5
6
4

2.5
10.0
40.0

7
5
6

0.64
2.50
10.00

6
5
6

Withdrawal Shakes
% Pretreatinent
(Mean + S. E.) 3

rn5o
(mg/kg)

Correlation
Coefficient

110.2 +

- 9.6
106.4 + 21.0
80.0 + 24.6
6

+6

76.7 + 16.9
124.0 + 49.2
42.0 + 22.6

74.5 + 17.9

96.4
50.0

+
+
-

16.6
23.3

14.2

-0.91

144.8

-0.54

21.4

-0.77

1. All drugs were administered i.p. 30 mins prior to post treatment observation.
2.

The number of rats employed per dose.

3.

Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of
morphine abstinence.

I-'
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by about 60 percent.

Pentobarbital was without effect on

withdrawal shakes until a dose of 10 mg/kg was administered.
Withdrawal shakes were reduced to 50 percent of pretreatment
when a 10 mg/kg dose of pentobarbital was administered.

The

highest dose of each sedative hypnotic employed produced a
substantial degree of sedation.

Regression analysis showed

no significant correlation between dose and effect for these
drugs.
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V.

A.

DISCUSSION

Morphine Withdrawal Body Shakes
Morphine withdrawal body shakes were reliably observed

upon the termination of continuous morphine infusion.

These

shakes were similar to those previously described by several
authors (for review see Gianutsos et al., 1975) in rats withdrawn from periodic injections of narcotic drugs.

However,

their rate of occurrence in the continuously infused rats was
higher than that usually seen in rats made dependent by intraperi toneal (Gianutsos et al., 1975) subdermal (Herz et al.,
1974) or oral (Lal et al., 1975) administration of narcotics.
Body shakes are related to narcotic withdrawal because they
are not seen in rats similarly infused with saline or in
morphine-infused rats which were not withdrawn (Table 2).
Additionally, these shakes were abolished by narcotic drugs
and the reinstatement of narcotic infusion (Table 5).

This

shake reducing action of narcotic drugs was antagonized by
the administration of the narcotic antagonist naloxone
(Table 6). Recently, it has been demonstrated that many morphine effects may be brought under stimulus control through
various procedures of conditioning (Lal et al., 1976).

Like

many of the other effects of morphine, the shake mitigating
action of this narcotic could be elicited by conditional
stimuli previously paired with morphine injections (Numan
et al., 1975).
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Withdrawal body shakes were selected as a sign of abstinence since they are a consistent, reliable and objective
measure.

Rats withdrawn from morphine for an eight-hour

period emitted an average of 25 body shakes in a 30 min observation period.

The frequency of withdrawal shakes remained

constant over many withdrawal sessions (Table 3).
olent shaking movements were easily detectable.

These viThe reli-

ability for detection of these body shakes was very high between independent observers.

For the purpose of establishing

inter-observer reliability two trained observers recorded
withdrawal body shakes during the same withdrawal session.
While observing the same withdrawal session these independent
observers recorded essentially the same number of body shakes.
In fact they were always within 2 percent of each other for
the total number of shakes occurring during the withdrawal
session.

The intense and violent nature of these shaking

movements make them an objective measure of withdrawal that
is easily distinguishable from body tremors or jerkin g type
movements.
Withdrawal observation was always started 8 hours
after the termination of morphine infusion.

There were sever-

al reasons for selecting 8 hours of withdrawal as the time
interval to start the withdrawal observation.

By the eighth

hour of withdrawal the shaking movements were fully developed
and occurring at a high rate.

Body shakes were found to start

to occur 3 hours after the morphine infusion was terminated
and to have reached a fairly constant frequency by 6 to 7
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hours of withdrawal.

Once the withdrawal shakes were fully

developed they remained at a fairly constant frequency for up
to 24 hours if the morphine infusion was not reinstated. Thus
the pretreatment shakes could be observed 8 hours after the
termination of morphine infusion, a test drug could then be
injected and given suffici e nt time to exert its action with
a high degree of certainty that the rate of occurrences

of

withdrawal shakes would remain unchanged except for drug action.

The fact that withdrawal shakes remained at a constant

intensity following 8 hours of abstinence is demonstrated by
the failure of a saline injection to influence the occurrence
of this withdrawal sign.
Morphine, methadone and fentanyl, potent narcotics,
blocked the occurrence o f withdrawal shakes (Table 5).

The

narcotic antagonist naloxone and pentazocine increased the
rate of withdrawal shakes slightly but not significantly
(Table 5).

However, naloxone effectively antagonized the

morphine induced blockade of withd rawal s h akes in a dose dependent manner (Table 6).
In addition to the blockade of withdrawal shakes produced by the narcotic agonist all the dopamine receptor
blockers investigated were found to mitigate the rate of
shaking with the exception of pimozide and pipamperone (Table
7).

These results are in agreement with previous findings

(Lal et al., 1971; Lal and Numan, 1976).

However there a p -

peared to be dramatic potency differences between those neuroleptics employed.

The butyrophenone neuroleptics, benperidol,
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haloperidol, oxiperomide, spiperone and spiramide, were specific in blocking withdrawal shakes in that they reduced them
at low doses which are well within the range of those producing the usual pharmacological actions of these drugs.

(+}Buta-

clamol, a derivative of benzocycloheptapyridoisoquinolinol,
exerted its antiwithdrawal effect at a low dose, that is, in
the dose range within which it produ ces its other psychopharmacological activities (Voith and Herr, 1975 ) . Similarly,
the member of the dibenzoxazepine series employed, loxapine,
also mitigated withdrawal shake behavior at do s es within its
pharmacological range for antidopamine activity (Coupet et
al., 1976).

The two phenothiazine neuro l ep t ics e mployed in

this study were only effective in blocking withdra wal shakes
at very high doses which also produce hypotonia and nonspecific

sedation, while pimozide, of the diphenylbutylpiperidine

series, and pipamperone did not totally block wi thdrawal
shakes even at the highes t dose tested.

From this comparison

it is clear that the butyrophenone, benzocycloheptapyridoisoquinolinol and dibenzoxazepine type neuroleptics are more
potent and specific in blocking withdrawal body shakes than
are the phenothiazines and diphenylbutylpiperidine type neuroleptics.
The dopamine receptor agonists tested for antiwithdrawal
potency also reduced the rate of withdrawal body shakes
(Table 8). Amphetamine, a drug which causes the release of
dopamine (McKenzie and Szerb, 1968; Carr and Moore, 1970) dose
dependently reduced body shakes as did the direct acting
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dopamine receptor agonist apomorphine (Ernst, 1967; Anden et
al., 1967).

L-DOPA, which is converted centrally into dop-

amine (Carlsson, 1971) reduced body shakes in a similar fashion.
With the exception of

a2aperone, all the adrenergic

blockers tested for anti-abstinence properties were without
effect (Table 12).

Azaperone is a sedative neuroleptic of

the butyrophenone series which is a potent alpha-noradrenergic
blocking drug (Niemegeers et al., 1974).

The adrenergic ago-

nists also seem to mitigate the occurrence of withdrawal
shakes.

However, only desmethylimipramine and clonidine ex-

hibited a significant dose dependent decrease in the occurrence of this withdrawal sign (Table 13).

Inhibition of cat-

echolamine synthesis by alpha-methyl-p-tyrosine (Nagatsu et
al., 1964) or storage by reserpine (Haggendal and Dahlstrom,

1972) decreased occurrence of withdrawal body shakes (Table
16) .
Agents that affect serotonergic mechanisms by either
increasing or decreasing the concentration of tr a nsmitte r
present at its recep tor site were without significant effect
on the occurrence of withdrawal body shakes (Table 17).

Man-

ipulation of gabaminergic mechanism also failed to influence
this withdrawal sign to any significant extent (Table 21).
The results achieved with the utilization of cholinergic agents provided a more consistent picture. A cursory
examination of the data indicates that anticholinergics increase withdrawal shakes while cholinergic decrease.

Although
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the anticholinergics used, atropine, benztropine, dexetimide
and scopolamine, did tend to increase body shakes, these increases failed to achieve significance (Table 18).

With the

exception of oxotremorine, all the cholinergics employed decreased body shakes (Table 19).

This effect achieved dose

related significance for only physostigrnine and pilocarpine.
The reduction in body shakes induced by pilocarpine is in
agreement with previous results (Hynes et al., 1976).
The involvement of nonspecific sedation in the reduction of withdrawal shakes was investigated by studying the
effect of several hypnotic drugs on this index of withdrawal.
Regression analysis revealed no significant correlation between the dose of chlordiazepoxide, flurazepam or pentobarbital and their effects on withdrawal shakes (Table 22).

How-

ever, a 40 mg/kg dose of chlordiazepoxide did completely reduce the occurrence of this withdrawal sign.
Body shakes measured here as an index of withdrawal
originate within the central nervous system.

There are

several lines of evidence which point to that conclusion.
Naloxone when injected into the brain of morphine dependent
animals elicits body shakes (Way et al., 1973; Laschka et al.,
1976a).

Narcotic withdrawal has also been attenuated by

lesion of the central nervous system (Pouzolo and Kerr, 1972).
Pilocarpine, a cholinergic agonist, is known to reduce both
withdrawal aggression and body shakes (Hynes et al., 1976).
The antiwithdrawal effect of pilocarpine is centrally mediated.

Its antiwithdrawal effects are not blocked by methyl-
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scopolamine, a peripherally active anticholinergic which does
not penetrate into the brain (Hynes et al., 1976).

These

lines of evidence clearly point to the central origins of
withdrawal body shakes.

It is therefore assumed that the

drugs which reduce body shakes are acting on the central nervous system. All drugs employed in this study have we11
established central mechanisms of action.

However, it is

possible that they could have peripheral actions which might
influence the expression of withdrawal body shakes.

It is

conceivable that a drug could inhibit withdrawal by preventing the muscular expression of withdrawal.

That is to say,

a drug could prevent the expression of a withdrawal sign
without having any effect on the underlying pathology.

D-

tubocurare would be an example of a drug that would produce
this type of effect, since it would produce muscular paralysis and thereby prevent the expression of withdrawal with
little or no effect on the underlying neuropathology.

None

of the drugs employed in this study are known to act in this
fashion, thus it can be reasonably assumed that they are exerting their antiwithdrawal effects on the central nervous
system.

B.

The Neurotransmitter Hypothesis of Antiwithdrawal Activity
Neuroleptics have man y important and well demonstrated

effects on neurotransmitters such as dopamine, norepinephrine,
serotonin,

(f'

aminobutyric acid and acetylcholine.

The anti-

withdrawal actions of neuroleptics may be mediated by their
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effects on the aforementioned neurotransmitters.
Previously, it was hypothesized that the antiwithdrawal
effectiveness of butyrophenones was the result of their dopamine receptor blocking action.

This hypothesis was based

upon the supersensitivity of dopamine-receptors seen during
morphine withdrawal

(for review see Lal, 1975; Lal et al.,

1976) and the effectiveness of haloperidol in reducing narcotic withdrawal in laboratory animals (Lal et al., 1971;
1971; Puri and Lal, 1973; Gianutsos et al., 1974; Lal and
Numan, 1976; Martin et al., 1974) and human patients (Karkalas
and Lal, 1973; Lal and Hynes, 1977).

The antiwithdrawal po-

tencies of the additional butyrophenone type neuroleptics
tested support this hypothesis.

The effective doses of those

neuroleptics with antiwithdrawal potency in producing other
pharmacological actions are given in Table 23.

As can be

seen from this table there is a correlation between the dose
of these drugs which antagonize the effect of apomorphine and
the antiwithdrawal dose.

Generally, those neuroleptics which

inhibit the effects of apomorphine at low concentrations also
reduced withdrawal body shakes at low doses.

There are sev-

eral exceptions, however; azaperone which is the most potent
neuroleptic in terms of its antiwithdrawal effect is the
least potent apomorphine antagonist.

Pimozide is another

exception in that it is a very poor inhibitor of withdrawal
body shakes but is a relatively potent apomorphine antagonist.
Even with these exceptions there appears to be a relationship
between antiwithdrawal and anti-apomorphine activity.

Table 23.

A Comparison of the Various Properties of Those Neuroleptics Tested for
Anti-Withdrawal Potency

Values in the Rat (mg/kg)l
50
Norepinephrine
Apomorphine
Antagonism
Catalepsy Ptosis Anta9:onism
0.33
8.0
1.5
0.98

En

ID50 (mg/kg)
Ampetamine
Anti-Withdrawal Antagonism
Azaperone

0.03

2.5

Spiperone

0.04

0.02

1. 2

0.036

0.27

0.0002

Benperidol

0.08

0.012

0.30

0.18

1.2

0.0005

+Butaclamol

0.12

6.31

-

-

.052

Loxapine

0.16

0.12

1.25

0.25

-

Oxiperomide

0.16

0.03

5.0

Haloperidol

0.17

0.038

2.1

Spiramide

0.19

0.016

Chlopromazine

0.49

Trifluoperazine
Pimozide
Pipamperone

10. 0

40.0

0.3

2.5

0.014

0.18

1.0

0.018

9.5

0.34

1.5

0.0021

0.60

0.60

2.3

2.3

0.71

0.74

0.08

7.2

0.6

2.5

0.034

1.64

0.1

40.0

0.18

4.5

0.011

11.02

2.5

3.0

2.7

0.97

16.5

1 values were derived from Janssen and Van Bever (1975).

I-'

"'"

w
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Apomorphine antagonism is a well established index of the ability of a drug to block brain dopamine receptors. The antiwithdrawal activity of neuroleptics may result from the inhibition
of brain dopamine receptors.

However, this hypothesis is not

supported by the fact that agents which stimulate dopamine
receptors also reduce withdrawal wet shakes.

The three dop-

amine receptor stimulants employed in this study all dose dependently reduce withdrawal body shakes. Although both dopamine receptor agonist and antagonist have the same effect on
body shakes, they differ with respect to their effects on
other withdrawal signs.

Butyrophenones, for example, have

previously been shown to block many other signs of narcotic
withdrawal.

These include hypothermia (Lal et al., 1971;

Cox et al., 1975) aggression (Puri and Lal, 1973; Gianutsos
et al., 1974; Lal, 1975); jumping (Takemori et al., 1976) and
responding for self-administration of narcotics (Hanson and
Cimini-Venema, 1972; Lal and Hynes, 1977).

Whereas dopa-

minergic agonists have been found to intensify many other
signs of narcotic withdrawal, pretreatment with L-DOPA, amphetamine or apomorphine enhances morphine withdrawal aggression (Lal et al., 1971; Lal, 1974) and withdrawal jumping
(Gunne, 1965; Herz, 1975).

Thus it is conceivable that the

action of dopaminergic agonists on withdrawal body shakes are
not related to dopaminergic activity. Drugs that stimulate
dopamine receptors are known to induce stereotyped behaviors
which consist of sniffing, licking and biting movements
(Ernst, 1967; Gianutsos et al., 1974).

The possibility
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exists that the induction of these stereotyped behaviors and
the occurrence of withdrawal shakes are not compatible. Thus
the withdrawn rat treated with a dopamine receptor agonist
would only be able to emit stereotyped movement and not body
shakes.
The marked potency of azaperone in blocking shakes
does not support this hypothesis. Azaperone is one of the
least potent anti-dopamine drugs tested yet the most potent
butyrophenone in blocking withdrawal shakes {Table 12). However, azaperone is a potent alpha-noradrenergic blocking
drug {Niemegeers et al., 1974).

It is thus possible that the

antiwithdrawal action of neuroleptics may be the result of
antinoradrenergic activity.

However, chlorpromazine which

is approximately an equally potent blocker of alpha adrenergic receptors {Janssen and Van Bever, 1975), is one of the
weakest blockers of withdrawal shakes {Table 7).

Addition-

ally, the alpha blocker phenoxybenzamine {Nickerson and Grump,
1949) failed to reduce body shakes as did the beta adrenergic
blocker propranolol {Nickerson and Collier, 1975).

The data

summarized in Table 23 do not support the hypothesis that
the antiwithdrawal activity of neuroleptics is the result of
antiadrenergic activity. As can be seen from this table
there is no correlation between the antiwithdrawal activity
of neuroleptics and antiadrenergic potency. Further evidence
against this particular hypothesis comes from the data on
adrenergic agonist drug.

One of the nost potent drugs in re-

ducing withdrawal body shakes is clonidine, an alpha receptor
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stimulant (Anden et al., 1970).

The tricyclic antidepressant

agents amitriptyline and desmethylirnipramine, which block
the re-uptake of norepinephrine into adrenergic nerve terminals (Byck, 1975), also decreases the occurrence of withdrawal body shakes (Table 13).
Since the discovery that the symptoms of Parkinsonism
could be relieved by drugs which act on either the cholinergic or the dopaminergic neuronal system, considerable evidence has suggested a possible reciprocal cholinergic-dopaminergic interaction in the central nervous system.

Neuro-

leptic drugs have been found to increase the release of
acetylcholine (Stadler et al., 1973; 1974; Lloyd et al.,
1973).

The possibility arises that neuroleptic drugs may be

exerting their antiwithdrawal effects through cholinergic
mechanisms.

If this is true then cholinergic drugs should

reduce withdrawal body shakes.

The results achieved here

indicate that cholinergic agonists tend to reduce withdrawal
shakes (Table 19).

However, this effect was significant for

only two of the five cholinergics studied. Cholinergic agonist do possess some of the other antiwithdrawal effects seen
after the administration of neuroleptics.

They decrease with-

drawal aggression (Hynes et al., 1976) and inhibit antagonist
precipitated morphine withdrawal jumping (Grumbach, 1969;
Bhargava and Way, 1972; Brase et al., 1974).

Thus it is con-

ceivable that the antiwithdrawal effects of neuroleptics are in
part mediated by cholinergic mechanisms.

However, if stimula-

tion of cholinergic receptors is responsible for inhibition of
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certain withdrawal signs then anticholinergics would be expected to increase withdrawal intensity or have no effect.
The results obtained in general conform with this expectation.

Those anticholinergic drugs tested produced some in-

crease in withdrawal shakes but this effect failed to achieve
significance (Table 18).

The possibility exists that these

withdrawn rats were showing the near maximum number of shakes
physiologically possible, thus it may not have been possible
to significantly increase their rate of occurrence by the
administration of anticholinergics. This hypothesis does not
explain the antiwithdrawal body shake effect produced by the
administration of dopaminergic agonist.

Apomorphine, amphet-

amine and L-DOPA have been found to increase acetylcholine
levels in the caudate (Sethyl and Van Woert, 1974) which suggests a decreasedlevel of acetylcholine at its receptor site.
In line with the above hypothesis, these agents would be expected to increase or have no effect on withdrawal shakes
which is the direct opposite of what was found. Thus a dopamine-acetylcholine hypothesis of withdrawal shakes is not
totally sufficient to explain all of the results.
In addition to the interaction between dopamine and
acetylcholine, it has also been postulated that dopamine interacts with serotonin (Cools, 1974) and GABA (Ladinsky et
al., 1976) in the central nervous system.

The results ob-

tained here do not support a role for either serotonin or
GABA in morphine withdrawal body shakes.

The administration

of serotonin receptor agonist or antagonist were without
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significant effect on the occurrence of body shakes observed
in morphine withdrawal (Table 17). Similarly, those agents
employed to modify GABA activity had no significant effect
on this index of withdrawal (Table 21).

Picrotoxin, a blocker

of GABA receptors (Galindo, 1969), however, did reduce body
shakes by about 70 percent at a dose of 0.64 mg/kg.
Neuroleptics in addition to their complex effects on
the various neurotransmitters, also produce a considerable
degree of sedation when given initially.

Sedation then may

be responsible for the antiwithdrawal activity of neuroleptic
drugs.

To test this possibility, several drugs of the seda-

tive hypnotic type were administered to withdrawn rats.
Neither chlordiazepoxide, flurazepam or pentobarbital had
any significant dose related effects on withdrawal body shakes
(Table 22).

The highest dose of these drugs emplo y ed did re-

duce body shakes.

The reduction was accompanied with a con-

siderable degree of sedation much greater than observed with
the various neuroleptics.

The degree of sedation produced

by the various neuroleptics does not correlate with the ability to reduce withdrawal body shakes. For example, haloperidol
has less of a sedative effect than chlorpromazine (Byck, 1975)
but is a more potent inhibitor of withdrawal shakes.

Seda-

tion does not appear to be an important factor in the reduction of withdrawal shakes produced by neuroleptics.
Of the neurotransmitters effected by neuroleptic drugs
it appears that effects on dopamine systems are the rrost important in terms of antiwithdrawal activity.

A relatively
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good correlation exists between antiwithdrawal activity and
antagonism of brain dopamine receptors for those neuroleptics
tested.

However, the antiwithdrawal effect of neuroleptics

may be mediated at least in part through cholinergic mechanisms.

This possibility arises because neuroleptics are

known to effect cholinergic mechanisms and the manipulation
of cholinergic systems was found to alter the occurrence of
withdrawal body shakes.

Administration of cholinergic ago-

nists was found to decrease withdrawal body shakes and neuroleptics, which cause the release of acetylcholine (Stadler
et al., 1973; 1974) similarly reduce this index of withdrawal.

c.

The Opiate Receptor Hypothesis of Antiwithdrawal Activity
It has been recently recognized (Clay and Brougham,

1975; Creese et al., 1975; Leysen et al., 1976) that butyrophenone type neuroleptics are among many non-narcotic drugs
which show binding affinity with opiate-binding sites in the
central nervous system.

It is possible t

.t the withdrawal

blocking action of butyrophenones is related to this binding
ability.

Besides the availability of actual binding data,

support for this hypothesis comes from studies with naloxone.
The administration of naloxone after the maximally effective
dose of azaperone, benperidol, oxipermide, haloperidol and
trifluoperazine in reducing withdrawal shakes produced a significant reversal of the antiwithdrawal effect of these
neuroleptics (Table 10).

Unlike the complete antagonism of
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morphine's action produced by naloxone, the only neuroleptic
to be completely antagonized by naloxone was azaperone (Table
15).

Naloxone antagonism in the case of benperidol, oxiper-

mide, haloperidol and
was far from complete.

trifluoper~zine

although significant,

Naloxone failed to antagonize the

antiwithdrawal body shake effect of spiperone, spirami d e, l oxapine, chlorpromazine and +butaclamol to any significant extent (Table 10).

These results do not support the idea that

the binding of neuroleptics to the opiate receptor is responsible for their antiwithdrawal effects.

Further evidence

against this theory comes from the fact that pimozide which
shows affinity for the opiate receptor (Creese et al., 1975)
does not block withdrawal wet shakes.
Opiate receptor binding is believed to be responsible
for many opiate actions, such as analgesia. We have been unable to detect any activity of these compounds in prolonging
tail-withdrawal latency, a reliable and sensitive test for
analgesia (Janssen et al., 1963; Niemegeers et al., 1976).
However, it has not yet been established that binding with
opiate receptor sites necessarily correlates with analgesia
in the case of nonnarcotic drugs.

It is possible that there

are different opiate receptors responsible for different actions of narcotic and nonnarcotic drugs.
Of the other drugs found to have antiwithdrawal potency
only one was antagonized to a significant extent by naloxone.
The reduction in withdrawal shakes produced by apomorphine
was reversed by the administration of naloxone (Table 11).
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This result is not unexpected in light of the fact that apomorphine is a narcotic.

However, the antiwithdrawal effects

of clonidine, amphetamine or pilocarpine were not significantly antagonized by naloxone.
These results suggest that some neuroleptics, but not
all, exert their antiwithdrawal effects to some extent by
binding with opiate receptors.

Although this explanation is

highly speculative, the resemblance between butyrophenones
with opiates in many other pharmacological actions (for review see Lal et al., 1975; 1976) provides some support for
this hypothesis.

It is difficult then to explain why some

butyrophenone neuroleptics which reduce withdrawal shakes are
not antagonized by naloxone.

The naloxone effect may be the

result of an increas e in the severity of the withdrawal syndrome and not a real antagonism of the neuroleptic.

Those

neuroleptics which are seemingly antagonized by naloxone may
not be able to reduce this withdrawal syndrome of increased
intensity.

The fact that the dose of naloxone, 5 mg/kg, em-

ployed in these experiments, does not produce an increase in
the number of body shakes fails to support this explanation
of the results.

It thus appears that naloxone is able to an-

tagonize the antiwithdrawal activity of some neuroleptics in
a specific manner.

However, even for those neuroleptics that

were significantly antagonized by naloxone that antagonism
was well below the total reversal level. This fact would indicate that in addition to the binding of these neumleptics
with the opiate receptor that they also reduce shakes by an
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additional mechanism that is not antagonized by naloxone.

It

appears that the binding of neuroleptics to opiate receptors
is in part responsible for the antiwithdrawal activity of
neuroleptics; however, this mechanism is not totally sufficient to explain the antiwithdrawal activity of these drugs.
Although the binding of nonnarcotic drugs to the opiate
receptor does not totally explain the antiwithdrawal activity
of these compounds, a role for the opiate receptor cannot be
ruled out.

It is possible that morphine or opiate-like com-

pounds present in the body could react with the opiate receptor to reduce withdrawal after nonnarcotic drug administration.
Withdrawal body shakes were observed eight hours after
the termination of morphine infusion which may be insufficient
time for the complete metabolism of all morphine present in
the system. This concentration of morphine is insufficient to
exert any significant pharmacological effects by itself.
Since neuroleptics are known to potentiate some of the effects
of morphine (Yelnosky and Gardocki, 1964; Edmonds-Seal and
Prys-Roberts, 1970) it is possible that those neuroleptics
with antiwithdrawal activity potentiate the morphine remaining in the system after eight hours of withdrawal.

This po-

tentiation of previously ineffective concentrations of morphine by the administration of neuroleptics may be responsible
for the reduction in withdrawal intensity.

If

t~is

mechanism

is operating to reduce withdrawal then naloxone would be expected to antagonize the reduction in body shakes.

The neuro-

leptic induced reduction in body shakes is, however, only
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partially antagonized in some cases, while in others unaffected
by naloxone administration, indicating that this mechanism does
not fully account for the neuroleptic induced reduction in
body shakes, although it may operate to a limited extent in
the antiwithdrawal activity of certain neuroleptics.

A simi-

lar mechanism may also be proposed to explain the amphetamine
induced reduction in body shakes. Amphetamine has been found
to augment the analgesia induced by morphine (Forrest et al.,
1977).

Administration of amphetamine to withdrawn rats could

potentiate the morphine still present after eight hours of
withdrawal. Again it would seem logical to expect naloxone to
antagonize the antiwithdrawal effect of this combination; however, no such antagonism was observed, suggesting that amphetamine's reduction in body shakes is mediated by another mechanism.

Although the actions of morphine can be potentiated

by a variety of drugs such as neuroleptics and amphetamines,
this potentiation does not appear to be responsible for the
antiwithdrawal activity of these drugs.
Much recent evidence has suggested that the body contains endogenous morphine-like compounds having many properties similar to those of narcotic drugs
stein, 1976).

(Hughes, 1975; Gold-

These endogenous morphine-like compounds could

be responsible for the antiwithdrawal activity of those nonnarcotic drugs tested. For example, neuroleptics may cause
the body to release these endogenous morphine-like substances
which in turn reduce withdrawal intensity.

The activity of

these endogenous morphine-like substances (endorphins) is
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reversed by the narcotic antagonist naloxone (Hughes, 1975;
Goldstein, 1976).

If the endorphins are mediating the reduc-

tion in withdrawal intensity induced by neuroleptics then
naloxone would be expected to antagonize this effect.

Since

naloxone is not able to antagonize the antiwithdrawal effect
of all neuroleptics this explanation is not very tenable.
This hypothesis is also not supported by the fact that neuroleptics do not produce analgesia which would be expected upon
endorphin release (Belluzzi et al., 1976; Hill et al ., 1976;
Unca et al., 1977).

This data fails to establish a role for

endorphins in the neuroleptic induced reduction of withdrawal body shakes.
D.

The Multiple Receptor Site Hypothesis of Antiwithdrawal
Activity
The probability exists that there is no single mecha-

nism by which neuroleptic drugs inhibit the expression of
morphine withdrawal body shakes.

Neuroleptics are known to

have many complex effects on the central nervous system and
any combination of these effects may be responsible for the
reduction in this withdrawal sign.

It is conceivable that

the reduction in body shakes induced by neuroleptics is the
result of an effect on several different neurotransmitters
and opiate receptors.

From the data presented here the most

likely combination of neurotransmitters are dopamine and
acetylcholine.

Naloxone was able to reverse that portion of

antiwithdrawal activity that was the result of opiate
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receptor binding but not that which was the result of neurotransmitter receptor binding.

It is also possible that in

addition to affecting opiate, dopamine and cholinergic mechanisms neuroleptics also bind with additional neurotransmitter
receptor sites to reduce narcotic withdrawal body shakes.
Many of the drugs that reduced withdrawal body shakes
have very different mechanisms of action suggesting that they
may share a common structural feature which is responsible
for antiwithdrawal activity.

The chemical structures of all

those compounds employed in this study are shown in Figure 3.
A cursory examination of these structures to ascertain a common structural feature in those drugs that inhibited withdrawal failed to show any apparent similarity.

This does not

rule out the existence of any structural similarity between
antiwithdrawal agent.

To demonstrate the presence of a

common feature would necessitate an in-depth computer analysis
for structure activity relationship.
The data obtained in this study suggest that neuroleptics reduce morphine withdrawal body shakes through activity
on several different receptor sites in the central nervous
system. Both narcotic and neurotransmitter receptor sites appear to be involved.

The neurotransmitter receptor sites

which appear to be the most important are those for dopamine
and acetylcholine.

The blockade of dopamine receptors and

the release of acetylcholine resulting from the administration
of a neuroleptic is one possible mechanism to explain antiwi thdrawal activity.

Other transmitters influenced by neuro-
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leptics can not be totally ruled out at this time but from
the data achieved in these experiments it is not highly probable that they are involved to any major extent .
In addition to the effects of neuroleptics on the various
neurotransmitters it is conceivable that an action on opiate
receptors is in part responsible for the reduction in withdrawal body shakes.

Neuroleptics may red uce withdrawal by

binding with both the dopamine and opiate receptor.

This

could explain why naloxone did not fully antagonize the effect of any neuroleptic.
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FIGURE 3

Chemical Structures of Those Drugs
Investigated for Antiwithdrawal
Potency
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SUMMARY AND CONCLUSIONS
Termination of continuous morphine infusion resulted in
the relabile occurrence of withdrawal body shakes (Table 2).
These body shakes were abolished by the administration of narcotic drugs

(Table 5).

Morphine withdrawal body shakes were

also dose dependently reduced by the administration of a
variety of neuroleptics (Table 7).

This reduction appears to

be related to inhibition of brain dopamine receptors.

Manip-

ulation of other transmitter systems affected by neuroleptics
points to a role for some of these neurotransmitters in the
reduction of body shakes.

Acetylcholine may play an import-

ant role in the antiwithdrawal activity of neuroleptics.

The

administration of cholinergic agents was found to produce
dose related decreases in withdrawal body shakes (Table 19).
It is highly possible that neuroleptics reduce withdrawal by
acting on both dopaminergic and cholinergic mechanisms.

The

reversal of the antiwithdrawal activity of some neuroleptics
by naloxone suggest a role for narcotic receptors

(Table 10) .

The possibility that neuroleptics bind with narcotic receptors thereby reducing withdrawal is not totally consistent
with all of the available data.

Naloxone was not able to

antagonize the antiwithdrawal activity of all neuroleptics
and even for those neuroleptics which were antagonized by
naloxone that antagonism was not complete, suggesting that
narcotic receptors are involved to a limited extent in the
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antiwithdrawal effects of some neuroleptics.

It is possible

that neuroleptic binding with both dopamine and narcotic receptor sites mediates the reduction in withdrawal body shakes,
with some neuroleptics having more of an effect on the dopamine receptor rather than narcotic receptors thus being less
likely to be reversed by naloxone.

Neuroleptic effects on

other neurotransmitters and receptor sites in conjunction with
narcotic receptors can not be totally discounted.
The data suggest neuroleptics reduce withdrawal body
shakes by complex effects on several different mechanisms
within the central nervous system.

Dopaminergic, cholinergic

and narcotic mechanisms, appear to be the most relevant.
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